

1st Edition

PEDIATRIC INTENSIVE CARE

HandbooK

Pharmacology & Practical Guidelines





1st Edition

PEDIATRIC INTENSIVE CARE

HandbooK

Pharmacology & Practical Guidelines

Introduction

The booklet in your hand is a humble effort from a group of health care professional working in the field of pediatric critical care medicine. It is not meant to be an alternative to textbooks.

Our aim is to produce a concise and practical handbook that include the most practical guidelines for common drugs used in PICU practice with its dosages and special precautions.

It includes also guidelines for management of most common diagnoses in PICU such as septic shock, traumatic brain injury, status asthmaticus and others.

The handbook also includes guidance on nutritional therapy since it is essential for recovery and survival of the critically ill children. We also included guidelines on the infection related patient safety indicators that we track each month (i.e. infection control, CLABSI, VAP and CAUTI).

We have selected some other simplified guidelines that would provide basic and pertinent information that are essential to PICU bedside physician such as the modes of pediatric mechanical ventilations; antibiotic lock and empirical antimicrobial therapy; electrolytes; blood products transfusion and cardiac arrest management.

The authors of this edition have looked carefully for the best evidence and the usual practices in PICU in accordance with the most current national and international recommendations at the time of publication. Care has been taken to ensure accuracy of the information presented but application of the guidelines information should always be used with caution using good clinical judgment that remains the professional responsibility of the health care practitioners.

The concept of having this handbook is to carefully design it to match patient's needs and to improve patient care outcome by using standardized approach using evidence-based literature whenever available.

We hope that you'll find this handbook helpful to you in day to day management of your child in PICU.

Regards,

Acknowledgment

First and foremost, we gave thanks and praise to our Almighty God, the author of knowledge and wisdom who gives us guidance and grace to make this project a reality.

Secondly, we have taken a lot of efforts in this project but it would not have been possible to the contributors who have provided ideas, invaluable guidance, constructive criticism and inspiring the team to work hard throughout this 1st edition of PICU handbook: pharmacology and practical guidelines project. No valuable words to express our heartfelt thanks for their support that has been an instrumental in making this project a success.

Our special thanks and gratitude to Dr. Amira Al Darwish and Dr. Jihad Zahraa, two of the major authors and contributors for their valuable time, dedication and assistance during the preparation and finalization of this project. Also, Our special thanks and gratitude to the reviewers, Dr. Hajer Almudaiheem and Dr. Najwa Alghamdi.

We would also like to thank all authors and contributors and special thanks to our secretary, Ms. Michelle Mella for her valuable contribution and friendly gesture.

Last but not the least, our appreciations to Ministry of Health team lead by Dr. Tareef Al Aama, Deputy Minister of Curative Affairs and Dr. Ibrahim Alharfi, Head of PICU Development Committee in MOH for their unconditional support to this distinguish project.

Yours sincerely,

Dr. Abdulaziz Alsoqati Consultant, Pediatric Intensivist Children's Specialized Hospital King Fahad Medical City

Table of Contents

Chapter	Topics
l.	Pharmacology Guidelines 1. Standard Concentrations of High Alert Pediatric Drugs 2. Infusion Rate Calculation 3. Drug Dosing Guidelines
П.	Electrolytes
Ш.	Clinical Management Guidelines 1. Septic Shock in Children 2. Status Epilepticus in Children 3. Management of Severe Traumatic Brain Injury in Children 4. Management of DKA in Children 5. Management Guidelines of Adrenal Crisis in Children
IV.	Infection Control Quality Measures 1. CLABSI 2. VAP 3. CAUTI
V.	Antibiotic Therapy 1. Antibiotic Lock Therapy Guidelines 2. Guidelines for Empirical Antimicrobial Therapy in Children
VI.	Nutrition in PICU
VII.	Pediatric Modes of Mechanical Ventilations Pediatric Non-invasive Positive Pressure Ventilation Pediatric Invasive Mechanical Ventilation Pediatric High Frequency Oscillatory Ventilation
VIII.	Blood Products Transfusion
IX.	Pediatric Cardiac Arrest Management 1. Pediatric Cardiac Arrest Algorithm 2. Pediatric Tachycardia with a Pulse and Poor Perfusion Algorithm 3. Pediatric Bradycardia with a Pulse and Poor Perfusion Algorithm
Х.	References

Standard Concentrations of High Alert Pediatric Drugs

	Standard Concentration			Diluents ** (Stability	Maximum Concentration
Drug Name	≤10 kg	>10 kg	Infusion Dose Range	= 12 hrs if prepared by nurse)	(Patients with fluid restriction)
Alprostadil (PGE1)	5 mc	:g/ml	0.01 – 0.4 mcg/kg/min	D5W, NS	20 mcg/ml §§
Amiodarone	2000 mcg/ml		LD: 5 mg/kg over 20 – 120 min; followed by: 5 – 15 mcg/kg/min. (Max. 1200 mg/24 hr)	D5W	5000 mcg/ml §§
Cisatracurium	1000 n	ncg/ml	1 – 4 mcg/kg/min	D5W, NS	2000 mcg/ml
Dobutamine	1000 mcg	/ml (RTU)*	2 – 20 mcg/kg/min (Max. 40 mcg/kg/min)	D5W, NS	5000 mcg/ml §§
Dopamine	1600 mcg/ml (RTU)* §§	3200 mcg/ml (RTU)* §§	2 – 20 mcg/kg/min (Max. 40 mcg/kg/min)	D5W, NS	6000 mcg/ml §§
Epinephrine	32 m	cg/ml	0.1 – 1.5 mcg/kg/min	D5W, NS	64 mcg/ml §§
Esmolol	10,000 mcg/ml		LD: 0.1 – 0.5 mg/kg over 1 – 2 min; followed by: 50 –200 mcg/kg/min (Max. 300 mcg/kg/min)	D5W, NS	20,000 mcg/ml §§
Fentanyl	10 m	cg/ml	0.5 – 6 mcg/kg/hr	D5W, NS	50 mcg/ml
Furosemide	2000 n	ncg/ml	0.05 – 2 mg/kg/hr	D5W, NS	10,000 mcg/ml
Heparin	50 units/ml		LD: 75 units/kg (round to nearest 100) over 10 min; followed by: 20 units/kg/ hr for children >1 yr and 28 units/kg/hr for infants (refer to hospital heparin infusion guide)**	D5W, NS	100 units/ml
Insulin	1 un	it/ml	0.01 – 0.2 unit/kg/hr	NS	1 unit/ml

Drug Name	Standard Concentration		Infusion Dose Range	Diluents ** (Stability = 12 hrs if	Maximum Concentration
Drug Name	≤10 kg	>10 kg	Initialiti Dose hange	prepared by nurse)	(Patients with fluid restriction)
Isoproterenol	20 m	cg/ml	0.05 – 2 mcg/kg/min	D5W, NS	64 mcg/ml §§
Labetalol	2000 n	ncg/ml	0.25 – 3 mg/kg/hr	D5W, NS	5000 mcg/ml
Lidocaine	4000 mcg	/ml (RTU)*	LD: 0.5 – 1 mg/kg over 1 – 2 min; followed by:10 – 50 mcg/kg/min	D5W, NS	8000 mcg/ml §§
Midazolam	1000 n	ncg/ml	0.5 – 6 mcg/kg/min	D5W, NS	5000 mcg/ml §§
Milrinone	200 mcg/ml		LD: 50 – 75 mcg/kg over 15 – 60 min; followed by: 0.25 – 1 mcg/kg/min.	D5W, NS	400 mcg/ml §§
Morphine	1000 n	ncg/ml	10 – 40 mcg/kg/hr	D5W, NS	2000 mcg/ml
Nitroglycerin	400 mcg/ml (RTU)*		0.25 – 5 mcg/kg/min (Max. 10 mcg/kg/min)	D5W – Glass, NS – Glass	400 mcg/ml
Nitroprusside – PFL*	200 mcg/ ml	400 mcg/ ml	0.3 – 3 mcg/kg/min (Max. 8 mcg/kg/min)	D5W	800 mcg/ml §§
Norepinephrine	32 mcg	g/ml §§	0.01 – 0.1 mcg/kg/min (Max. 1 – 2 mcg/kg/min)	D5W, NS	80 mcg/ml §§
Octreotide	5 mc	:g/ml	1 – 4 mcg/kg/hr	D5W, NS	10 mcg/ml
Phenylephrine	40 mcg	g/ml §§	0.1 – 0.5 mcg/kg/min	D5W, NS	80 mcg/ml §§
Salbutamol (Albuterol)	100 mcg/ml		0.5 – 5 mcg/kg/min	D5W, NS	250 mcg/ml
Terbutaline	20 mcg/ml		LD: 2 – 4 mcg/kg over 5 – 10 min; followed by: 1 – 12 mcg/kg/hr	D5W, NS	100 mcg/ml
Vasopressin	0.2 uni	t/ml §§	0.01 – 0.12 unit/kg/hr (vasodilatory shock with hypotension resistant to other treatments)	D5W, NS	1 unit/ml §§

Infusion rate Calculation

Infusion rate Calculation:

Rate = Ordered amount of drug x pts weight (kg) x Time x Total Volume Stock dose x 1000 if needed

- 1. Ordered amount of drug: Physician Order.
- 2. Patient Weight: Patient weight per Kilograms.
- 3. Time: If the order per minute will multiply by 60 and if the order per hour will multiply by one.
- Total volume: The final volume after adding Dilution to the original stock based on the Standard or Maximum concentration.
- 5. Stock Dose: Pure Medication strength according to the company production
 - A. If the stock in mg and the order in microgram: Multiply by 1000
 - B. If the stock in mg and the order in mg: no need to multiply.
 - C. If the stock in microgram and the order in microgram: no need to multiply.

Example 1: Your 8 kg patient has Epinephrine Infusion ordered at 0.1 mcg/kg/min. Medication ampoule came as 1 mg in 1mL, What is the Infusion rate?

Rate = $\frac{0.1 \times 8 \times 60 \times 32}{1 \times 1000}$ = 1.5 ml / hr.

0.1 : Is the Physician Order.

8 : Is the patient weight Per Kg.

60 : The order per Minute .

32 : Total Dilution (1ml Stock volume + 31 ML D5W as per (*Standard Concentration of High Alert Pediatric Drugs)

1: is the original Medication Stock .

x1000 : the order per Microgram and the stock per Mg.

Example 2: Your patient has Fentanyl ordered at 2 mcg/kg/hr. the patient weight is 6 kg. Then Drug comes as 100 mcg in 2 ml , What is the infusion rate?

Rate = $\frac{2 \times 6 \times 1 \times 10}{100}$ = 1.2 ml / hr.

2 : is the physician order
6: Patient weight per Kg.
1: one hour (the Order per hour)
10: total dilution (2ml Stock volume + 8 ML D5W as per) *Standard Concentration of High Alert Pediatric Drugs)
100: Original Medication Strength Example 3: Your patient has Furosemide ordered at 0.5mg/kg/hr. the patient weight is 10 kg. Then Drug comes as 20 mg in 2 ml , What is the infusion rate?

Rate = $\frac{0.5 \times 10 \times 1 \times 10}{20}$ = 2.5 ml / hr. 0.5 : is the physician order 10: Patient weight per Kg. 1: one hour (the Order per hour) 10: total dilution (2ml Stock volume + 8 ML D5W as per (*Standard Concentration of High Alert Pediatric Drugs) 20: Original Medication Strength

Example 4 : Your patient has Insulin ordered at 0.05 Unit /kg/hr. the patient weight is 8 kg. Then Drug comes as 100 International Unit in 1 ml , What is the infusion rate?

Rate = $\frac{0.05 \times 8 \times 1 \times 50}{50}$ = 0.4 ml / hr.

0.05 : is the physician order 8 : Patient weight per Kg. 1: one hour (the Order per hour) 50 : total dilution (0.5 ml Stock volume + 49.5 ML NS as per (*Standard Concentration of

High Alert Pediatric Drugs)

50: Original Medication Strength .

*: Refer to the table Standard Concentrations of High Alert Pediatric Drug.

Drug Dosing Guidelines

Acetaminophen			10-15 mg/kg/dose every	Comments:	
Analgesic,Non-narcoticAntipyretic	PO	Neonate, infant & children	4 – 6 hours > 45 kg do not exceed 3 g/day Max: 75 mg/kg/day	 Infusion over 15 minutes High dose may cause hemolytic anemia in 	
	IV	Neonate, infant & Children	< 10 kg: 7.5 mg/kg/dose every 6 hours >10 kg: 15 mg/kg/dose every 6 hours Max: 75 mg/kg/day (3,750 mg/ day) – (Max 60 mg/kg/ day for up to 2 years old)	patient with G6PD deficiency	
		Children & adoles- cents >50 kg	1 g every 6 hours or 650 mg every 4 hours Max: single dose 1 g, daily dose 4 g		
Acetazolamide Diuretic Carbonic Anhydrase 			Edema: 5 mg/kg/dose every 8 – 12 hours		
Inhibitor	PO & IV	Infant & children	Metabolic alkalosis: 3-5 mg/kg/dose every 6 – 8 hours Max Adult dose: 500 mg as single dose		
Acetylcysteine	Acetamino	phen poisoning:			
Antidote Mucolytic Agent	PO	Loading Dose (LD): dose)			
	PO		Maintenance: 70 mg/kg every 4 hours for 17 doses. (Max. 7.5g/dose)		
		LD: 150 mg/kg (Ma minutes	ax: 15 g) infused over 60		
	IV	4 hours	g (Max: 5 g) infused over kg (Max: 10 g) infused over		
	Nebulizer	Infant: 1 – 2 ml of 2 hours	0% solution every 6 – 8		
	INEDUIIZER	Children: 3 – 5 ml c 6 – 8 hours	of 20% solution every		

Acyclovir	HSV infect	ion:		Comments:
Antiviral Agent	Dissem- inated, CNS, skin, eye or mouth disease:	IV: 15 -20 mg/ kg/dose every 8 hours Treatment duration: Cutaneous and mucous mem- brane infection: 14 days CNS or dissem- inated infection: 21 days		 Obese patient should be dosed using ideal body weight (IBW) Monitor IV site for phlebitis IV acyclovir > 15 mg/kg/dose may be associated with an increased risk of nephrotoxicity
	HSV encep	ohalitis:		
	Neonate, infant & children:	IV: 10-20 mg/kg/do to 21 days	ose every 8 hours for 14	
	Children >12 yrs:	IV: 10 mg/kg/dose 21 days		
	Herpes Sir	nplex Mucocutaneo		
		IV	10 mg/kg/dose every 8 hours for 7 to 14 days	
		PO: children ≥ 2 yrs	1000 mg/day divided in 3 to 5 doses for 7 to 14 days (Max: 80mg/kg/day)	
	HSV gingiv	vostomatitis:		
		PO:	20 mg/kg/dose 4 times daily for 7 days (Max: 200 mg/dose)	
	Varicella zo	oster: (shingles, herp	es zoster, and chickenpox)	
		IV:	10 mg/kg/dose every 8 hours for 7 to 14 days or until no new lesions for 48 hours	
		PO: children ≥ 2 years:	20 mg/kg/dose 4 times daily for 5 days (Max daily dose: 3200 mg/ day)	

Adenosine	Paroxysma	al supraventricular tachycardia:			
Antiarrhythmic Agent	Neonate:		Comments:		
		initial dose: RAPID IV push 0.1 mg/kg ; if not effective increase dose by 0.05 -0.1 mg/kg every 1 – 2 minutes (Max single dose: 0.3 mg/kg)	 Administer by rapid IV/IO push over 1 – 2 seconds followed by Saline flush 		
	Infant & ch	ildren:			
		rapid IV initial: 0.1 mg/kg (Max: 6 mg) If not effective give 0.2 mg/kg (Max: 12mg)			
Alprostadil	Patent Duo	ctus Arteriosus			
Prostaglandin	Neonate,	Continuous IV infusion: 0.05 – 0.1 mcg/kg/minute (Max: 0.4 mcg/kg/minute)	Comments: - May cause apnea, flushing, bradycardia		
	children:	Decrease the rate to the lowest effective dose (no adverse effect) down to 0.005 mcg/ kg/minute	and hypotension.		
Alteplase: (tPA)	Occluded central venous catheter:				
Thrombolytic Agent	≤ 10 kg	0.5 mg diluted in 1 ml NS			
	> 10 to <30 kg	1 mg/ml (Max: 2mg/2ml)			
	≥ 30kg	2mg in 2 ml			
	Instill in lumen over 1 to 2 minutes; leave in lumen for 1 to 2 hours then aspirate out of catheter ((Do not infuse into patient))				
	Parapneumonic effusion:				
	Infant > 3 months, children and adolescents:				
	Intrapleural: 4 mg in 40 ml NS 1st dose with one-hour dwell time repeated every 24 hours for 3 days				
Amikacin	Neonate: (s	sepsis & meningitis) by post neonatal age (PNA)		
Antibiotic (Aminoglycoside)	12 hours	ays & ≥ 2kg: 15 – 20 mg/kg/day divided every ays & ≥ 2 kg: 30 mg/kg/day divided every 8	Comments: Draw trough level within 30minutes prior to 3rd dose		
	Infants, chi	ldren & adolescents:	Trough level: severe infection: < 8 mcg/L, Moderate infection:		

	General dosing, severe, susceptible infections: IM, IV: 15 – 22.5 mg/kg/day divided every 8 hours or 15 – 20 mg/ kg/dose once daily. (Max: 30 mg/kg/day divided every 8 hours) CNS infection: Meningitis: IV: 20 – 30 mg/kg/day divided every 8 hours. Ventriculitis: intra-ventricular/ intrathecal: 5 – 30 mg/day (Use preservative free preparation). Cystic fibrosis, pulmonary infection: Tendiliane Ideniary (M. 10 mg/kg/day and integrate 9 hours)	
	Traditional dosing: IV, IM: 10 mg/kg/dose every 8 hours Extended interval dosing: IV: 30 mg/kg/dose every 24 hours	
	Mycobacterium, avium complex infection:	
	IV: 15 – 30 mg/kg/day divided every 12 – 24 hours (Max: 1500mg/day)	
	Tuberculosis, drug resistant:	
	Infant, children &adolescents: IM, IV: 15 – 20 mg/kg/ dose once daily as part of multiple drug regimen. (Max: 1000mg/day) (ATS/CDC/IDSA)	
	Peritonitis:	
	Continuous Intra-peritoneal: Loading dose: 25mg/L of dialysate, Maintenance dose: 12mg/L	
Aminophylline	Apnea of prematurity:	
Bronchodilator Respiratory Stimulant	IV: loading dose: 5 – 8 mg/kg/dose. Infused over 30 to 60 minutes Maintenance: 2 -6 mg/kg/day divided every 8 to 12 hours (Start maintenance dose 8 to 12 hours after the loading dose)	Comments: - Consider withholding next dose if heart rate is greater than 180 beats per minute.
69	Obstructive airway disease:	 Use ideal body weight for obese patients
	Patient not currently receiving aminophylline/theophylline: LD: 6 mg/kg IV bolus	
	Initial Maintenance Infusion of Aminophylline (theophylline equivalent) at infusion rates adjusted for age: 6 weeks to 6 months of age: 0.3 to 0.5 mg/kg/hour. 6 months to 1 year of age: 0.6 to 0.7 mg/kg/hour. 1 to 9 years of age: 1 mg/kg/hour. 9 to 12 years of age: 0.9 mg/kg/hour. 12 to 16 years of age: 0.9 mg/kg/hour. Cardiac decompensation, liver dysfunction, shock, sepsis with organ failure: 0.2 mg/kg/hour	Avoid using amino- phylline if you cannot measure the level

Amiodarone • Antiarrhythmic	Supravent (VT):	ricular Tachycardia with a Pulse, Pulseless VF/V	T, Perfusing tachycardia	
Agent, Class III	IV	For Pulseless VF/VT: Boluses of 5 mg/kg may be repeated up to 2 times (Max. 15 mg/ kg total) For SVT, perfusing VT: LD: 5 mg/kg IV infusion given over 20 to 60 minutes can be repeated up to 2 times. (Max: 15 mg/kg, 300 mg/dose), preferably in a central vein.	pulmonary fibrosis - Can cause hypo- tension which may	
		Maintenance Dose: 5 – 15 mcg/kg/minute IV continuous infusion (10 to 20 mg/kg/day). (Max: 2200 mg /day) Duration of maintenance infusion is usually 24 to 72 hours, followed by oral maintenance therapy if indicated.	respond to reducing the infusion rate.	
		LD: 10 to 15 mg/kg/day, followed by mainte- nance dose.		
	PO	P.O: Maintenance Dose: 5 to 10 mg/kg/day orally given once daily or in divided doses twice daily 7 to 10 days.	-	
Amlodipine	Hypertens	ion:	` 	
 Antihypertensive Agent Calcium Channel Blocker Dihydropyridine 	1 year to ≤ Initial 0.05 daily Maintenan divided tw	Comments: - Dose titration should be made at 5 to 7 day intervals		
	Children > 2.5 – 5 mg	6 years: once daily (Max: 10 mg/day).	-	
Amoxicillin	General do	osing:		
Antibiotic Penicillin	Neonate: F	P.O: 20 – 30 mg/kg/day divided every 12 hours		
	Otitis media, acute: Infant < 2 months: 30 – 40 mg/kg/ day divided every 8 hours Infant ≥ 2 months and children oral 80 – 90 mg/kg/divided every 12hours			
	UTI prophy	/laxis (hydronephrosis vesicoureteral reflux):		
	10 – 15 mg	g/kg once daily		
	Mild to moderate infection			
	Infant & ch	ildren: 25 – 50 mg/kg/day divided every 8 hours	(Max: 500 mg/dose)	
	Severe infection:			
	80 – 100 m	ng/kg/day divided every 8 hours		
	Endocardi	tis, prophylaxis:		
	infant, chil	dren & adolescent: P.O 50 mg/kg 1 hour before	procedure (Max: 2g/ dose)	

Amoxicillin and	General do	sing: Dose based on amoxicillin content				
ClavulanateAntibioticPenicillin	PO	Infants < 3 months: 30 mg /kg/day divided every 12 hours Infants ≥ 3 months, children & adolescents: 25 – 45mg /kg/day divided every 8 – 12 hours Otitis media: 90mg/kg/day divided every 12 hours				
69		Infant < 3 months: <4 kg: 30mg/kg/dose even kg/dose every 8 hours	y 12 hours, >4kg: 30mg/			
	IV	Infant >3 months – 12 years: 30mg/kg/dose ev hours in severe infection	Infant >3 months – 12 years: 30mg/kg/dose every 8 hours OR every 6			
		Children > 40kg: 1.2 g every 8 hours				
Amphotericin B	General do	osing:	Comments:			
(Conventional) Antifungal Agent 	IV	1mg/kg/day once daily (Max. 1.5 mg/kg/day for very sick patient).	 Can cause allergy (IV infusion should be over 2 – 6 hours) 			
Go	Consider li insufficiend	posomal amphotericin B if there is renal cy.	 Can cause hypo- kalemia Can cause nephro- toxicity (need good hydration). 			
Amphotericin B	General do	osing:				
(Liposomal)	IV: 3 – 5 m	g/kg/dose once daily				
Ampicillin:	General dosing: infants, children and adolescents.		Comments:			
AntibioticPenicillin	Mild to moderate infection: IM, IV	100 – 200 mg/kg/day divided every 6 hours. Max:4 g/day	 Can cause hypersen- sitivity and anaphylac- tic reaction 			
	Severe infection: IM, IV	200 – 400 mg/kg/day divided every 6 hours Max: 12 g/day				
	Endocar- ditis: IV	200 mg/kg/day divided every 4 – 6 hours in combination with other antibiotics (Max. 12 g/day)				
	Intra-ab- dominal infection, compli- cated: IV	200mg/kg/day divided every 6 hours (Max. single dose 2000 mg)				
	Meningi- tis: IV	200 – 400mg/kg/day divided every 6 hours (Max: 12g/day)				

	Peritonitis (CAPD) Continu- ous am- bulatory peritoneal dialysis:	Intraperitoneal 125 mg per liter of dialysate for 2 weeks	
Arginine	Pituitary fu	nction test: infant, children and adolescents:	Comment:
		IV: 0.5 g/kg over 30 minutes (Max dose: 30 g)	The dose is based on Arginine hydrochloride
	Hyperamm	onemia, acute:	product.
		ccinic acid lyase (ASL) or argininosuccinic acid (ASS) deficincy:	
		IV: LD: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day	
		phosphate synthetase (CPS) ornithine mylase (OTC), N-Acetyl glutamate synthetase iciency:	
		IV: LD: 200 mg/kg followed by a continuous IV infusion of 200 mg/kg/day	
	Unconfirme	ed/pending diagnosis:	
		IV LD: 600 mg/kg followed by a continuous IV infusion of 600 mg/kg/day If ASS and ASL are excluded as diagnostic possibilities reduce dose to 200 mg/kg/day	
	Urea cycle	disorders, chronic therapy:	
		ASL or ASS: Oral: 400 – 700 mg/kg/day in 3 to 4 divided doses CPS: Oral: 170 mg/kg/day in 3 to 4 divided doses	

Aspirin Non-steroidal An-	Analgesic:		Comment: It is not recommended to		
ti-inflammatory		Infant, children and adolescent <50 kg: PO: 10 – 15 mg/kg/dose every 4 – 6 hours. Max: the lesser value of 90 mg/kg/day or 4000 mg/day Children and adolescent ≥50 kg: 325 – 650 mg every 4 – 6 hours Max: 4000 mg/day	use aspirin in - Children < 12 years who are recovering from chickenpox or having flu like symptoms		
	Antiplatelet	effect:			
	1 – 5 mg/k	g/dose once daily			
	Fontan sun mg/kg/dos	gery, postoperative primary prophylaxis: 1 – 5 e once			
	Kawasaki o	Kawasaki disease:			
	to 14 days	00 mg/kg/day divided every 6 hours for up until fever resolves for at least 48 hours then ose to 1 – 5 mg/kg/day once daily			
Atropine Anticholinergic	Bardycardi	a: infant, children and adolescents:			
	IV, IO	0.01 – 0.02 mg/kg/dose (Max dose: 0.5 mg, Max total dose: 1 mg) (minimum dose of 0.1 mg for infants less than 5 kg is no longer recom- mended as per new AHA/PALS 2015 guidelines)			
	Endotracheal: 0.04 – 0.06 mg/kg/dose may repeat once if needed				
	Organophosphate or carbamate insecticide:				
	IV, IM	Initial: 0.05 – 0.1 mg/kg repeat every 5 to 10 minutes as needed. (Doubling the dose if previous dose does not induce atropinization)			
Azithromycin	Mild to moderate infection:				
AntibioticMacrolide	PO	5 day regimen: 10 – 12 mg/kg/dose (Max: 500 mg), on day 1 followed by 5 – 6 mg/kg (Max: 250 mg) once daily for whole duration			
RA	3 day regimen: 10 mg/kg/day once daily for 3 days (Max: 500mg/dose)				
	Serious infection:				
	IV	10 mg/kg once daily (Max. 500 mg/day)			

Bosentan	Pulmonary arterial hypertension:		
Endothelin Re- ceptor Antagonist	Neonates:	persistent pulmonary hypertension (PPHN)	Comments: Monitor LFT's. May cause hypotension, peripheral edema and thrombocytopenia.
	- PO: 1mg/	kg/dose every 12 hours	
	Infant and	children:	
	- weight ba	sed dosing:	
		Initial dose: 0.75 – 1 mg/kg/dose twice daily fo 62.5 mg) Maintenance dose: 2mg/kg/dose twice daily (f mg, >40 kg: 125mg)	,
	Fixed dosir	ng:	
		 5 to < 10kg: initial 15.6 mg daily for 4 week nance dose of 15.6 mg twice daily 10 to 20 kg: initial: 31.25 mg daily for 4 ween nance dose of 31.25 mg twice daily >20 to 40 kg: initial: 31.25mg twice daily for maintenance dose of 62.5 mg twice daily >40kg: initial: 62.5 mg twice daily for 4 ween nance dose of 125 mg twice daily 	eks, increase to mainte- or 4 weeks, increase to
	Drug induced extrapyramidal symptoms:		Comments:
Benztropine Anticholinergic Agent	PO IM	Children ≥3 years: 0.02 – 0.05 mg/kg/dose 1 to 2 time daily	 May cause anhidrosis, hyperthermia and tachycardia
	IV	Adolescents: 1 – 4mg every 12 -24 hours	 May cause anticholin- ergic effects
Budesonide	Asthma: Ne	ebulization:	
Corticosteroid	Infants: Initial: 0.25mg twice daily or 0.5mg once daily (Max: 1mg/day) Children and adolescents: initial: 0.25 mg twice daily (Max: 1mg/day)		
Calcium Chloride • Calcium Salt, Electrolyte Supplement	Hypocalce	mia:	Comments: Monitor: serum calcium, serum magnesium, heart rate and site for extravasation
		children: 10 – 20 mg/kg/dose (0.1 – 0.2 ml/kg) nours if needed 1000 mg	
		Ca CL 10% = 1.36 meq/ml = 0.7 mmol/ml = emental Ca/ml)	

Calcium Glu-	Hypocalcemia:	Comments:	
conate • Calcium Salt, Electrolyte Supplement	Infants, children and adolescents: dose expressed as calcium gluconate IV: 200 – 500 mg/kg/day as a continuous infusion or in 4 divided doses Max dose: infants and children: 1000 mg/dose Max dose: adolescents: 2000 mg/dose	Calcium gluconate 10% = 100 mg/mL= elemental calcium 9 mg/mL = 0.46 mEq/mL Monitor: serum calcium, serum	
	Symptomatic (seizure, tetany):	magnesium, heart rate	
	Infants, children and adolescents: dose expressed as calcium gluconate IV: 100 – 200 mg/kg/dose over 5 to 10 minutes		
	Hyperkalemia:		
	Calcium gluconate 100 mg/kg/dose over 5 minutes. May repeated in 10 minutes		
Calcium Polysty-	Hyperkalemia:	Comments:	
rene Sulfonate (Resonium	Neonates, Children: Oral/Rectal: 0.5 to 1 g/kg/dose	Powder resin must be mixed with water prior to	
Calcium):	May repeat the dose Q4-6H PRN (usual max. 30 – 60 g/dose)	administration	
Captopril	Heart failure (afterload reduction):	Comments:	
Angiotensin converting en- zyme inhibitor (ACEI)	Infants: P.O 0.3 – 2.5 mg/kg/day divided every 8 – 12 hours Children and adolescent: 0.3 – 6 mg/kg/day divided every 8 – 12 hours (Max: 150mg/day)	 Can cause hyper- kalemia, hypotension and cough Heart failure indica- tion: Initiate therapy 	
	Hypertension:	at lower end of range	
Gy	Infants: initial: 0.15 – 0.3 mg/kg/dose in 1 – 4 divided doses (Max: 6mg/kg/day) Children and adolescents: initial: 0.3 – 0.5 mg/kg/dose every 8 hours (Max: 6 mg/kg/day) (Max daily dose: 450 mg/day)	and titrate upward to prevent symptomatic hypotension. Contraindication: in patient with bilateral renovascular disease unilateral/bilateral renal	
		artery stenosis	

Carbamazepine	Epilepsy:			
Anticonvulsant	Infants and children: <6 years	initial 10 – 20 mg/kg/day divided twice or 3 times daily as immediate release tablets or 4 time daily as suspension. Increase dose every week until optimal response and therapeutic level achieved. Max daily dose: 35 mg/kg/day	Comments: - You may need to adjust the dose after first month following initiation of therapy because	
	6 to 12 years:	initial: 100 mg twice daily (immediate release tablets or extended release tablets or 50 mg of suspension 4 times daily (200 mg/day) increase by up to 100 /day at weekly intervals Usual maintenance dose: 400 – 800 mg/ day (Max daily dose: 1000 mg/day)	Carbamazepine undergoes hepatic autoinduction. - Therapeutic level: 17 – 51 mcmol/L equivalent to 4 – 12 mcg/ml	
Caspofungin • Antifungal Agent, Echino- candin	Infants 1 to	<3 months: IV 25mg/m2/dose once daily	Comments: May cause decreased serum albumin, increased serum alkaline phosphatase, increased	
69	Infants and children 3 months to 17 years: loading dose: IV: 70 mg/m2/dose on day 1, maintenance dosing: IV: 50 mg/m2/dose once daily May increase the dose to 70 mg/m2/dose once daily if clinical response inadequate (Max: 70 mg)		serum ALT, increased se- rum AST and increased bilirubin	
	Caution:			
	Patient receiving carbamazepine, dexamethasone, efavirenz, nevirapine, phenytoin or rifampin and any other enzyme inducers consider 70mg/m2/dose once daily (Max:70mg)			
Cefazolin	General do	sing, susceptible infection:		
Antibiotic, Cephalosporin,	Infants, chi	Idren and adolescents: IV or IM		
1st Generation	mild to moderate infections:	50 – 100 mg/kg/day divided every 8 hours. Max dose: 1000 mg/dose (3g/day)		
GD	Severe infections:	100 – 150 mg/kg/day divided every 8 hours. Max dose: 2000mg/dose (6g/day)		
	Peritonitis: Intra-peri-	Intermittent: 20 mg/kg every 24 hours in the long dwell		
	toneal:	Continuous: loading dose: 500mg/ liter of dialysis maintenance: 125 mg/liter of dialysis		

Cefepime Antibiotic, Ceph- alosporin, 4th Generation	General do Infants, chi	sing: Idren and adolescents:		
	Mild to moderate infection:	IV: 50 mg/kg/dose every 12 hours Max dose: 2000 mg/dose	Comments: Cystic fibrosis patients with more resistant pseu-	
69	Severe infection:	50 mg/kg/dose every 8 – 12 hours Max dose: 2000 mg/dose	domonas isolations (MIC ≥ 16 mg/L) may require 50 mg/kg/dose every 6	
	Meningi- tis, Cystic fibrosis, acute pulmonary exacerba- tion:	50 mg/kg/dose every 8 hours	hours (consult ID when using this dose)	
Cefixime	General do	sing: PO		
Antibiotic, Ceph- alosporin, 3rd Generation	Infants, children ≤ 45kg:	8mg/kg/day divided every 12 to 24 hours, Max daily dose: 400mg/day		
69	Children weighing >45kg and adoles- cents:	400mg daily		
Cefotaxime	General do	sing:		
Antibiotic, Ceph- alosporin, 3rd	Neonate:			
Generation	≤ 7 days ol	days old: <2 kg: 100 mg/kg/day divided every 12 hours, >2 kg:100 – 150 mg/kg/day divided every 8 – 12 hours		
CA CA	\geq 7 days of	7 days old: 150 – 200 mg/kg/day divided every 6 – 8 hours		
	Infants, children and adolescents: IV, IM			
	Mild to moderate infection:	100 – 150 mg/kg/day divided every 6 – 8 hours (≥ 50 kg: 1000 – 2000 mg every 6 – 8 hours) Max daily dose: 6 g/day		
	Severe infection/ Pneumo- nia:	150 – 200 mg/kg/day in divided doses every 6 – 8 hours (Max: 2 g per dose)		
	Peritonitis:	Intraperitoneal: intermittent: 30 mg/kg/dose every 24 hours : Continuous: LD: 500 mg/liter of dialysate, maintenance: 125 – 250 mg/ liter		
	Menin- gitis:	IV: 200 – 300 mg/kg/day divided every 6 – 8 ho	ours (Max: 2 g per dose)	

Ceftazidime	General do	sing:	
Antibiotic, Ceph- alosporin, 3rd	Infants, chi	ldren and adolescents:	
Generation	mild to moderate infection: IV, IM	90 – 150 mg/kg/day divided every 8 hours (Max daily dose: 3 g/day)	
	Severe infection/ Menin- gitis/ Cystic fibrosis: IV	150 – 200 mg/kg/day in divided doses every 8 hours (Max daily dose: 6 g/day)	
	Urinary tract infection:	infant and children (2 – 24 month) IV: 100 – 150 mg/kg/day every 8 hour	
	Peritonitis:	Intraperitoneal: intermittent: 20 mg/kg/dose every 24 hours in the long dwell Continuous: LD: 500 mg/liter of dialysate, maintenance: 125 mg/liter	
Ceftriaxone	General do	sing: Infants, children and adolescents:	Comments:
 Antibiotic, Cephalosporin, 3rd Generation 	Mild to moderate infection:	IV: 50 – 75 mg/kg/dose once daily Max dose: 1 g/day	May cause cholelithiasis, sludging in gall bladder
	Severe infection/ Meningi- tis: IV:	100 mg/kg/day divided every 12 – 24 hours Max daily dose: 4 g/day	
Cefprozil	General do	sing: PO	
Antibiotic, 2nd generation cephalosporin	mild to moderate infection:	7.5 – 15mg/kg/dose twice daily, Max single dose: 500mg	
Cefuroxime	General do	sing: Infants, children and adolescents:	
Antibiotic, Cephalosporin, 2nd Generation	Mild to moderate infection:	P.O: 20 – 30 mg/kg/day divided twice daily. Max dose: 500 mg/dose IV, IM: 75 – 100 mg/kg/day divided every 8 hours. Max dose: 1500 mg/dose	
	Severe infection:	IM, IV: 100 – 150 mg/kg/day divided every 6 – 8 hours Max dose: 1500 mg/dose.	

Chloral Hydrate	Sedation, a	anxiety:	
 Hypnotic, Sedative 	Infants and children: Oral, rectal: 25 - 50 mg/kg/dose every 6 – 8 hours as needed, Max dose: 500 mg/dose		Comments: May cause cardiac arrhythmia, hypotension
	Hypnotic:		
69		Oral, rectal: 50 mg/kg/dose at bed time.	
	Sedation, r	non-painful procedure:	
		Oral, rectal: 50 – 75 mg/kg/dose 30 – 60 minutes prior to procedure, may repeat 30 minutes after initial dose if needed, Total Max dose: 120 mg/kg or (1 g total for infant, 2g total for children)	
Ciprofloxacin	General do	sing, susceptible infection:	Comments:
Antibiotic, Fluoro- quinolone	Oral:	20 – 30 mg/kg/day divided every 12 hours, Max dose: 500 mg/dose	 May cause gastric up- set, diarrhea, dyspep- sia, nausea, vomiting
69	IV:	20 – 30 mg/kg/day divided every 12 hours, Max dose: 400 mg/dose	and headache - May enhance the QTc prolonging effect of moderate or high risk QTc prolonging agents.
	Complicate	ed UTI or pyelonephritis:	
	Oral:	20 – 40 mg/kg/day divided every 12 hours for 10 to 21 days, Max dose: 1.5 g/day	
	IV:	18 – 30 mg/kg/day divided every 8 hours for 10 to 21 days, Max dose: 1.2 g/day	
	Cystic fibro	osis:	
	Oral:	40 mg/kg/day divided every 12 hours, Max dose: 2g/day	
	IV:	30 mg/kg/day divided every 8 to 12 hours, Max dose: 1.2 g/day	
Cisatracurium	Paralysis s	keletal muscle relaxation: IV:	Comments: Rare but important life threating side effect are: bradycardia, bron- chospasm, flushing and hypotension
 Neuromuscular Blocker Agent, Non-depolar- izing 	infant & children <2 years old:	0.15 mg/kg over 5 – 10 seconds	
	Children ≥ 2 years old:	0.1 – 0.15 mg/kg over 5 – 10 seconds	,
	Contin- uous IV infusion:	1 – 4 mcg/kg/ minute Max: 10 mcg/kg/minute	

Clarithromycin	General do	sing:	Comments:
Antibiotic, Mac- rolide	Infants, children and ado- lescents:	P.O: 15 mg/kg/day divided every 12 hours (Max. single dose: 500 mg)	 Prolonged QT interval on ECG May increase serum levels of carbamaz- epine, cvclosporine
Gið	Mycobacte	rium avium complex infection (MAC):	and tacrolimus
	Prophy- laxis: P.O:	15 mg/kg/day divided every 12 hours	
	Treatment: P.O:	15 – 30 mg/kg/day divided every 12hours. Max. single dose: 500 mg	
Clindamycin	General do	sing:	Comments:
Antibiotic, Anaerobic	Infants, children and ad- olescent: IM, IV:	20 – 40 mg/kg/day divided every 6 – 8 hours Max daily dose: 2700mg/day	May cause diarrhea, pseudomembranous co- litis, rash, thrombophlebi- tis, thrombocytopina, ab- normal hepatic function tests and jaundice
	P.O:	10 – 40 mg/kg/day divided every 6 – 8 hours, Max daily dose: 1800 mg/day	
Clobazam	Lennox-Gastaut syndrome:		Comments:
Anticonvulsant, Benzodiaz- epine	Children and ado- lescents: ≤ 30 kg:	initial: 5mg once daily for \geq 1 week, may increase to 5 mg twice daily for \geq 1 week, then increase to 10 mg twice daily (Max daily dose: 20 mg/day).	May increase dosage slowly every 5 – 7 days.
69	>30kg: initial:	5 mg twice daily for ≥ 1 week, may increase to 10 mg twice daily for ≥ 1 week then in- crease to 20 mg twice daily (Max daily dose: 40 mg/day).	
		neralized or partial, py or adjunctive therapy:	
	Infants and children:	initial: PO: 0.5 – 1 mg/kg/day in two divided doses, (Max initial dose: 5 mg/day) Max daily dose: 10 mg/day	
	Children 2 -16 years:	initial: 5 mg once daily, usual range: 10 – 20 mg/day or (0.3 – 1 mg/kg/day in divided doses twice daily. Max daily dose: 40 mg/day	

Clonazepam	Seizure dis	orders:	Comments:	
 Anticonvulsant, Benzodiaz- 	Infants and	children < 10 years old or \leq 30 kg:	May cause behavior change, increase	
epine			secretions	
	Children ar	nd adolescent > 30 kg:		
	doses, may seizures ar	not to exceed 1.5 mg given in 3 divided y increase by 0.5 – 1 mg every third day until e controlled or adverse effects seen ce dose: 0.05 – 0.2 mg/kg/day. (Max: 20 mg/		
Clonidine	Hypertensi	on:	Comments:	
 Analgesic Antihyperten- 	children an	d adolescents:	 May cause hypo- tension. 	
sive (Alpha Adrenergic Agonist)	initial: P.O: 5 – 10 mcg/kg/day in divided doses every 6 – 12 hours, increase gradually as needed Usual range: 5 – 25 mcg/kg/day in divided doses every 6 hours. Max dose: 0.9 mg/day		 Do not discontinue clonidine abruptly (can cause rebound hypertension or withdrawal). 	
	Opioid withdrawal:			
	P.O: 1 – 5 n dose)	ncg/kg/dose every 6 hours (Max. 200 mcg/		
Cloxacillin	Infants and	l children: P.O, IV:		
 Antibiotic, Penicillin (Antistaphylo- coccal)) 	Mild to moderate infections	100 – 150 mg/kg/day in divided doses every 6 hours. Max daily dose: 4 g /day		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Severe infections	150 – 200 mg/kg/day in divided doses every 4 – 6 hours. Max: 2 g/dose (12 g/day)		
	Meningi- tis: IV:	200 mg/kg/day in divided doses every 6 hours. Max: 12 g/day		
Codeine and	Children ar	nd adolescents:		
Acetami- nophen • Analgesic, Narcotic		d on codeine: /kg/dose every 4 – 6 hours g/dose		

Colistin	General do	sing: Infants, children and adolescents:	Comments:
 Antibiotic, Mis- 			- Intraventriculary: Via
cellaneous	75,000 – 150,000 unit/kg/day in divided doses every 6 – 12 hours		an external ventricular drain (EVD), which
R	Cystic fibro	sis, pulmonary infection:	is clamped for 1 h &
S S S	90,000 – 15 hours	50,000 unit/kg/day in divided doses every 8	 released May cause CNS tox- icity: dose reduction
	Intraventric	ular/Intrathecal:	may reduce neurolog-
	Intraventric	150,000 - 300,000 units/day ular: 60,000 – 300,000 units/day – 2 ml of preservative free normal saline once	ic symptoms
	Inhalation:		
		2 years: 0.5-1 Million Units (MIU) Q 8 HR (Max:), Pre-medicate with salbutamol	
Cotrimoxazole	Dose is bas	sed on the trimethoprim (TMP) component	Comments:
 Antibiotic, Sulfonamide 	Infants \geq 2 months, children and adolescents:		 Not recommended for use in infants < 2
Derivative	General dosing:	P.O, IV: 6 – 12 mg TMP/kg/day in divided doses every 12 hours Max: 160mg TMP/ dose	months - May cause kernicter- us in newborns, blood
50	Pneumocystis jirovecii pneumonia (PCP):		dyscrasias
	Treatment:	P.O/ IV: 15 – 20 mg TMP/kg/day in divided doses every 6 – 8 hours for 21 days	
	Prophy- laxis:	PO: 5mg TMP/kg/day in divided doses every 12 hours for 3 consequent or alternative day. Max daily dose: 320 mg TMP/ day	
	UTI:		
	Treatment: P.O, IV:	8 – 12 mg TMP/kg/day in divided doses every 12 hours for 7 – 14 days	
	Prophy- laxis: P.O:	2 mg TMP/kg/dose once daily	
Dantrolene	Manageme	nt of malignant hyperthermia:	
Skeletal Mus- cle Relaxant	IV:	2.5 mg/kg continuous repeated till symptoms subside or cumulative dose of 10 mg/kg	
 Skeletal Mus- 	laxis: P.O: Manageme	nt of malignant hyperthermia: 2.5 mg/kg continuous repeated till symptoms	

Desmopressin	Diabetes inipidus: children and adolescents:		adolescents:	Comments:	
 Hormone, Vasopressin Analog 	oral: 0.05 mg twice daily titrate to desired response Dose range: 0.1 – 0.8 mg/day in 2 to 3 divided doses			Closely monitor serum sodium levels and urine output.	
Ro		DDAVP nasal spray eliver fixed doses in	: 10 mcg (0.1 ml) incre-		
		Infants: ≥ 3 months and children:	initial: 5 mcg/day in 1 to 2 divided doses, usual range: 5 – 30 mcg/day in two divided doses.		
		Adolescent:	5 – 40 mcg/day in 1 - 3 divided doses.		
		Adult:	20 mcg/day in 2 divided dose.		
	IV, SubQ: Initial dosa	ge range: 0.1 to 1 m	icg in 1 or 2 divided doses		
Dexamethasone	Infants, chi	Idren and adolescer	nts	Comments:	
Corticosteroid, Glucocorticoid	Airway edema or extuba- tion:		, IV: 0.25 - 0.5 mg/kg/dose every 6 lax dose: 10 mg/dose). - For extuba		
	Anti-in- flamma- tory:	kg/day in divided c	ose range: 0.02 – 0.3 mg/ loses every 6 - 12 hours ose: 0.75 – 9 mg/day	2 doses before extu- bation and 2 – 4 after extubation	
	Asthma exacerba- tion:	P.O, IM, IV: 0.6 mg/ Max dose: 16mg/c	/kg once daily for 2 days. lose		
	Cerebral edema:	dose			
	Croup:	P.O, IM, IV: 0.6 mg/ 16 mg	/kg once daily, Max dose:		
Dexmedetomidine	Sedation			Comments:	
Alpha2-Adren- ergic Agonist; Sedative	LD: 0.5 – 1 mcg/kg/hour followed by maintenance infusion 0.2 – 1 mcg/kg/ hour		- May cause brady- cardia		
Dextrose:	Hypoglyce	mia:		Comments:	
			- 1 g/kg/dose rose, 1 - 2 ml/kg/dose of	- May cause localized phlebitis and extrava- sation. Central line is preferred	

Diazepam	Convulsive	disorder: Acute treatment:	Comments:	
Benzodiazepine	Rectal gel: children 2 6 – 11 year	5 years: 0.5 mg/kg s: 0.3 mg/kg 0.2 mg/kg	Comments: Round dose to the near- est 2.5 mg increment, not exceeding a 20 mg/dose, may be repeated in 4 to 12 hours if needed	
Digoxin	Infants, chi	Idren and adolescents:	Comments:	
 Antiarrhythmic agent, Cardiac 	Total Digita	lizing dose (TDD):	 Based on lean body weight and normal 	
Glycoside		: **Give ½ of the TDD for the initial dose, then ne TDD for each of two subsequent doses at ntervals	renal function - May cause nausea vomiting, abdominal	
	P.O	infants 1 – 24 months: 35 - 60 mcg/kg 2 – 5 years: 30 – 45 mcg/kg 5 – 10 years: 20 – 35 mcg/kg >10 years: 10 – 15 mcg/kg	pain and thrombocy- topenia	
	IV:	infants 1 – 24 months: 30 – 50 mcg/kg 2 – 5 years: 25 – 35 mcg/kg 5 – 10 years: 15 – 30 mcg/kg >10 years: 8 – 12 mcg/kg		
		ce dose: **maintenance dose: if < 10 year our, if > 10 year once/day	-	
	P.O:	Infants 1 – 24 months: 10 – 15 mcg/kg/day 2 – 5 years: 8 – 10 mcg/kg/day 5 – 10 years: 5 – 10 mcg/kg/day > 10 years: 2.5 – 5 mcg/kg/day		
	IV:	infants 1 – 24 months: 7.5 – 12 mcg/kg/day 2 – 5 years: 6 – 9 mcg/kg/day 5 – 10 years: 4 – 8 mcg /kg/day >10 years: 2 – 3 mcg/kg/day		
Diphenhydramine • Antihistamine,	Dystonic reaction, Allergic reaction (severe) & anaphy- laxis:		Comments: - May cause sedation,	
Sedative	IV, IM, P.O	1 – 2 mg/kg/dose given every 6 hours Max single dose: 50 mg/dose	paradoxical excite- ment in children - Not recommended for use in neonates	
Dobutamine	Infants, chi	Idren and adolescents:	Comments:	
Adrenergic Agonist Agent	Continuous desired res	s IV infusion: 2 – 20 mcg/kg/minute titrate to ponse	- Compatible with: D5W, NaCl 0.9%, D5 NaCl 0.45%, D5 NaCl 0.9% May cause arrhythmias	
Domperidone • Dopamine Antagonist, Gastrointes- tinal Agent, Prokinetic	Children:		Comments:	
	P.O:	0.2 – 0.4 mg/kg/dose every 6 – 8 hours Max: 30 mg/day	 May increase QTc interval Consider close ECG monitoring in patients on other drugs cause QTC prolongation 	

Dopamine	Infants, chi	Idren and adolescents:	Comments:	
Adrenergic Agonist Agent	Continuous IV infusion:		- The hemodynamic effects of dopamine	
	 Intermed effect (m tropic eff High dos 	cg/kg/minute titrate to desired response liate dosage: 5 -10 mcg/kg/minute, beta ainly inotropic effects with some chrono- fects age: 10 – 20 mcg/kg/minute. Alpha adrener- ts, potent vasoconstriction	are dose dependent - May cause arrhyth- mias	
Enoxaparin Anticoagulant, 	Infants 1 to <2	Treatment: Subcutaneous (Sub Q): 1.5 mg/kg/dose every 12 hours	Comments: - Monitor antifactor Xa	
Low Molecular Weight Heparin (LMWH)	months:	Prophylaxis: Sub Q: 0.75 mg/kg/dose every 12 hours	levels 4 hours after the dose - Adiust dosage to	
()	Infants ≥ 2 months.	Treatment: Sub Q: 1 mg/kg/dose every 12 hours	achieve target antifac- tor Xa levels (for the treatment 0.5 – 1 unit/	
Gp	children & adoles- cent:	Prophylaxis: Sub Q: 0.5 mg/kg/dose every 12 hours	ml, for prophylaxis 0.1 – 0.3 unit/ml).	
Epinephrine	Infants, chi	Idren and adolescents:	Comments:	
Adrenergic Agonist Agent	Nebs: Racemic epi- nephrine (2.25%),	children ≥ 4years and adolescents: 0.5 ml diluted with 3 -5 ml of NS. Every 3 – 4 hours	 Dose <0.3 mcg/kg/ minute generally produce β adrenergic effects Dose >0.3 mcg/kg/ minute generally pro- duce alpha adrenergii effect May cause tachy- cardia ,arrhythmia, pulmonary edema an extravasation 	
	Croup: (laryn- gotrache- obronchi- tis), airway edema: Nebs:	Racemic epinephrine (2.25%): 0.05 – 0.1 ml/ kg Max dose:0.5 ml) diluted in 2 ml NS, may repeat dose every 20 minutes		
	Hypersen- sitivity/ Allergic reaction: IM, SubQ:	0.01 mg/kg (0.01 ml/kg/dose of 1:1000 solution(1mg/1ml)) not to exceed 0.3 – 0.5 mg every 5 – 15 minutes		
	Asystole/ pulseless arrest and Bradycar- dia:	IV, I.O: 0.01 mg/kg (0.1 ml/kg of 1:10,000 solution) every 3 – 5 minutes, Max single dose: 1 mg ETT: 0.1 mg/kg (0.1ml/kg of 1:1000 solution) every 3 – 5 minutes, Max. single dose: 2.5 mg		
	Brady- cardia, Hypoten- sion/sho- ck, fluid resistant	Continuous infusion: IV, I.O: 0.05 – 2 mcg/kg/ minute titrate dosage to desired effect		

Epoprostenol	Pulmonary	hypertension:	Comments:	
(Flolan) Prostacyclin, PGI2	Infants, chi	ldren and adolescents:	 May cause flushing, jaw pain, headache, 	
		Continues infusion: initial: 1 – 2 ng/kg/minute titrate the dose by 1 to 2 ng/kg/minute every 15 minutes until dose limiting side effects are noted or tolerance limit to epoprostenol is observed	hypotension and nausea	
		Usual range: 2 – 60 ng/kg/minute		
		Chronic dosing ≥ 1year of therapy: 50 – 80 ng/kg/minute		
Erythromycin	Infants, chi	ldren and adolescents:	Comments:	
 Antibiotic, Macrolide 	General do	sing, susceptible infection:	 May cause abdominal cramping, nausea and 	
	P.O base: 3 (Max: 2 g/c	0 – 50 mg/kg/day divided every 6 – 8 hours lay)	vomiting - May cause hyper-	
Gið	hours	oionate: 15 – 50 mg/kg/day divided every 6 lose: 4 g/day	 trophic pyloric steno- sis and pseudomem- branous colitis 	
	Pertussis:	Infant and child: PO 10 mg/kg/dose every 6 hour, Max daily dose: 2 g/day		
	Proki- netic (GI motility) agent:	P.O: 3 mg/kg/dose 4 times daily may increase as needed to effect. Max dose: 10 mg/kg or 250mg		
Esmolol	Infants, chi	Idren and adolescents:	Comments:	
 Antiarrhythmic Agent (Class II), 	Hypertensi	ve emergency/urgency:	 Monitor blood pressure 	
Beta Adrener- gic Blocker)		Continuous IV infusion: 100 – 500 mcg/kg/ minute Bolus: 100 – 500 mcg/kg over 1 minute, followed by an infusion of 25 – 100 mcg/kg/ minute titrating as needed. Max: 500 mcg/ kg/minute	 May cause extravasa- tion, thrombophlebitis, necrosis and blistering 	
	Supraventr	icular tachycardia (SVT):		
		IV bolus: 100 – 500 mcg/kg over one minute followed by a continuous IV 25 – 500 mcg/ kg/minute titrate in 25 to 50 mcg/kg/minute increment Max: 1000 mcg/kg/minute		

Etomidate	Induction & maintenance of anesthesia:		Comment:		
General Anes- thetic		Children > 10 years Initial: 0.2 to 0.6 mg/kg over 30 to 60 seconds.	 It may cause adrenal suppression 		
69	Procedure sedation: 0.1 – 0.3 mg/kg (repeated doses may be needed)				
Factor VIIa (Novo-	Children and adolescents:		Comments: - Dose and interval may be adjusted based		
Seven) Antihemophilic 	Hemophilia A or B with inhibitor:				
Agent		Dose range: 35 – 90 mcg/kg Usual dose: 90 mcg/kg every 2 hours until hemostasis is achieved or until the treatment judged ineffective	upon the severity of bleeding and degree of hemostasis achieved		
	Surgical int	erventions:	 Rounding factor VII dose to nearest 		
		90 mcg/kg immediately before surgery repeat at 2 hours intervals as needed	vial size		
	Congenital	factor VII deficiency:			
		Bleeding episodes and surgical interventions: 15 – 30 mcg/kg every 4 – 6 hours			
Factor VIII (Ko-	Children ar	nd adolescents: General dosing:	Comments:		
genate®) Antihemophilic	Minor hemorrhage:		- Calculated dosage should be adjusted to		
Agent		10 – 20 units/kg repeat every 12 -24 hours until bleeding resolve or healing achieved	the actual vial size		
	Moderate h	nemorrhage:			
		15 -30 units/kg repeat every 12 -24 hours			
	Severe/life-	threatening hemorrhage			
		30 -50 units/kg repeat every 8 – 24 hours until threat is resolved			
Fentanyl Opioid, Analgesic	Infants, children and adolescents:		Comments: May cause respiratory depression and apnea		
	Intermittent dose: 1 – 2 mcg/kg/dose every 2 – 4 hours as needed				
GD	Continuous	s infusion: 0.5 – 5 mcg/kg/hour titrate to effect			

Flecainide Antiarrhythmic Agent, Class Ic	Infants ≤ 6 months: P.O:	initial 50 mg/m2/day divided every 8 – 12 hours	Comments: - May titrate dose at 4 day intervals - Higher doses have		
69	Infants > 6 months, children & adoles- cent: P.O:	initial 100 mg/m2/day divided every 8 – 12 hours Max daily dose: 200 mg/m2/day	 Ingrier doses have been associated with an increased risk of proarrhythmic effects Reserved for resistant dysrhythmias 		
	Alternate d	ose:	- Milk products may de-		
	hours, usua hours	O: initial 1 – 3 mg/kg/day divided every 8 al range: 3 – 6 mg/kg/day divided every 8 dose: 8 mg/kg/day	crease bioavailability		
Fluconazole Antifungal 	General dosing:	IV, P.O: 6 – 12 mg/kg/dose once daily Max daily dose: 600 mg/day	Comments: - May cause nausea, vomiting, hypokalemia and elevations in liver function tests		
Agent	Oro- pharyn- geal candidi- asis:	6 mg/kg/dose on day 1 once daily, followed by 3 mg/kg/dose once daily (Max. day one: 200 mg/day, Max. subsequent dose: 100 mg/day)			
	Peritonitis:	intraperitoneal, IV, P.O: 6 – 12 mg/kg/dose every 24 – 48 hours Max single dose: 400 mg /dose			
Fludrocortisone	Pediatric:				
Corticosteroid	Adrenal insufficiency, autoimmune, Addison's disease:		Comments:		
		P.O: 0.05 – 0.2 mg daily	Sodium retention, hypokalemia, hyper-		
	Congenital adrenal hyperplasia:		tension, fluid retention		
		infants and children: 0.05 – 0.2 mg daily in 1 -2 divided doses. Max: 0.3mg/day	causing edema, growth suppression		
Flumazenil • Antidote, Ben- zodiazepine	Infants, children, adolescents		Comments:		
	Reversal of	benzodiazepine sedation/ overdose:	Does not reverse effects of narcotics		
		0.01 mg/kg (Max dose: 0.2mg/dose) given over 15 seconds with repeat doses of 0.01 mg/kg given every minute. Maximum total cumulative dose of 0.05 mg/kg or 1 mg whichever is lower			

Fosphenytoin • Anticonvulsant, Hydantoin	Status epile	eptics:	Comments: - May cause lethargy, nystagmus, hirsutism, gingival hyperpla- sia and cardiac arrhythmia - Rate of intravenous administration 1 – 3 mg PE/kg/minute		
		LD: IM, IV: 15 – 20 mg PE/kg (Maximum rate: 150 mg PE/minute) Max dose: 1500 mg PE			
		 Fosphenytoin should always be prescribed and dispensed in mg of phenytoin equivalents (PE) Phenytoin 1 mg = fosphentoin 1 mg PE Start the maintenance therapy 12 hours after the loading dose Free (unbound) phenytoin serum concentrations should be monitored closely in patients with renal/hepatic disease or in those with hypoalbuminemia Monitor phenytoin therapeutic level (10-20 mcg/ml = 40 – 79 mcmol/L) 			
Furosemide	Edema: Infa	ants, children	Comments: - Start oral furosemide by 1 – 2 mg/kg/day then gradually in-		
Loop Diuretic		P.O: 1 – 6 mg/kg/dose every 12 – 24 Hours (Max dose: 6 mg/kg/dose)			
		IV, IM: 1 – 2 mg/kg/dose every 6 – 12 hours	crease to the desired		
		Continuous IV infusion: 0.05 mg/kg/hour; titrate dosage to clinical effect (Max: 1 mg/kg/hour)	effect. - Don't exceed adult dose (20 mg) unless the desired effect was not achieved. - Monitor serum electrolytes (May cause hypokalemia, hypercalciuria, hypomagnesemia anu metabolic alkalosis)		
Gentamicin	General do	sing: Infants, children and adolescents	Comments: - Level should be taken 30 min. pre 3rd dose (trough level should be less than 2 mcg/ mL) - May cause ototoxicity and nephrotoxicity,		
Antibiotic, Aminoglyco- side	Conven- tional dosing:	IM, IV: 2.5 mg/kg/dose every 8 hours			
	Extend interval dosing:	4.5 – 7.5 mg/kg/dose every 24 hours in patient with normal renal function			
	VP-shunt infraction, ventricu- littis: Ventricu- littis: Ventricu- littis:		 monitor renal function Loop diuretics may potentiate ototoxicity 		
	Cystic fibrosis,	Conventional dosing: IM, IV: 3.3 mg/kg/dose every 8 hours			
	pulmonary infection:	Extend interval dosing: IV: 10 – 12 mg/kg/ dose every 24 hours			

Glucagon	Hypoglycemia, persistent:				Comments: Monitor blood glucose closely			
Antihypoglyce- mic Agent	IM, IV, SubQ: 0.02 – 0.03 mg/kg/dose (Max dose: 1 mg) may repeat dose in 20 minutes if needed							
	Fixed dose: age directed: < 6 years 0.5 mg, > 6 years 1 mg							
Glycopyrrolate • Anticholinergic Agent	Control of secretions (chronic):					Comments:		
	P.O:					May cause tachycardia, mucous plugs		
	IM, IV:	4 – 10 mcg dose: 200 i		every 3 – 4 h	ours (Max	1		
Haloperidol	Agitation (acute); psychosis:							
Antipsychotic	IM, IV	0.05 – 0.15 needed. M		ay be repeat ose.	ed hourly as	-		
Heparin	Systemic h	eparinizatio	n:			Comments:		
Anticoagulant	Loading Dose:	75 units/kg by the Mair		er 10 minute lose	s followed	 APTT therapeutic level 60 – 85 seconds, antifactor Xa level of 		
	Mainte- nance dose:	Infants < 1 year: 28 units/kg/hour Children >1 year: 20 units/kg/hour				 (0.35 - 0.7 units/ml) Antidote: protamine sulfate May cause thrombo- 		
	APTT	Bolus, U/kg	Hold, Mints	rate change%	Repeat APTT	 May cause thrombo- cytopina, vasospasm and hyperkalemia 		
	<50	50	0	+10	4 h			
	50-59	0	0	+10	4 h			
	60-85	0	0	0	Next day			
	86-95	0	0	-10	4 h			
	96-120	0	30	-10	4 h			
	>120	0	60	-15	4 h			
Hyaluronidase	Infants, children and adolescents:					Comments: - Antidote for hyper- osmotic solution		
Antidote, Extrava-	Extravasation:							
69	SubQ, intrader- mal:	use 5 separate 0.2 ml injection of a 150 units/ ml solution into extravasation site at the leading edge				 calcium, potassium etc.) Administer as soon as possible (preferably within one hour) after extravasation is recognized 		

Hydralazine	Hypertensi	on:	Comments:	
 Antihyper- tensive; Vasodilator 	initial dose: Dose range	0.75 mg/kg/day in 2 to 4 divided doses, (Max 10mg/dose) e: 0.75 – 7.5 mg/kg/day in 2 to 4 divided doses, adually over 3 to 4 weeks (Max: 200 mg/day)	May cause orthostatic hypotension, paradoxical hyportension and tran- sient agranulocytosis	
	Hypertensi	ve emergency/urgency:		
	Usual range	il: 0.1 – 0.2 mg/kg/dose e: 0.2 – 0.6 mg/kg/dose every 4 to 6 hours as ax dose: 20 mg/dose		
Hydrochlorothi-	Edema and hypertension:		Comments:	
azide	Max. dose: infant & up	ng/kg/day once or twice per day to 2 years 37.5 mg/day 00 mg/day).	 May cause hypergly- cemia, hyperuricemia, hypercalcemia, hypochloremic alka- losis, hypokalemia, 	
	Bronchopu	Imonary dysplasia (BPD):	hyponatremia and	
Antihyperten- sive, Diuretic, Thiazide	infant: 3 -4	mg/kg/day	 hypomagnesemia. Administer with food improves absorption 	
Hydrocortisone • Corticosteroid	Adrenal insuffi- ciency (Acute):	IM, IV: infant and children: 1 – 2 mg/kg/dose IV bolus, then 25 – 150 mg/day in divided doses every 6 – 8 hours	Comments: - May cause edema, hypokalemia, hyperg- lycemia, sodium and water retention and growth suppression - Oral dosage form can be administer with food or milk to decrease Gl upset - Withdraw therapy with gradual tapering of dose if the duration more than one week	
	Anti-in- flamma-	P.O: 2.5 – 10 mg/kg/day or 75 – 300 mg/m2/ day divided every 6 – 8 hours		
	tory:	IM, IV: 1 – 5 mg/kg/day or 30 – 150 mg/m2/ day divided every 12 – 24 hours		
	Septic shock:	IV: initial: 1 – 2 mg/kg/day (100 mg/m2/day) in divided doses every 6 hours (in catecho- lamine- resistant shock and suspected or proven adrenal insufficiency)		
HYDROmorphone	Acute pain, moderate to severe:		Comments:	
Analgesic, Opioid	Infants > 6	months weighing > 10kg::	 May cause CNS and respiratory depression 	
	P.O	Immediate release: 0.03 – 0.06 mg/kg/dose every 4 hours as needed	 May cause nausea, vomiting, constipa- tion, hypotension, 	
	IV 0.01mg/kg/dose every 3 to 6 hours		bradycardia and urinary retention - Naloxone is the	
RA	Continuous IV infusion:			
	0.003 - 0.0	05 mg/kg/hour	antidote	

Ibuprofen	Analgesic a	and Antipyretic:	Comments:
Nonsteroidal Anti-inflam- matory Drug (NSAID)		mg/kg/dose every 6 to 8 hours as needed, dose: 400mg, Max daily dose: 40 mg/kg/day)	 Use with caution in patients with renal or hepatic failure and low platelet Contraindicated in patients with active GI bleeding and ulcer disease To be given after meal
Imipenem	General do	sing, susceptible infection:	
Antibiotic, Carbapenem	IV: 60 – 100 dose: 4000) mg/kg/day divided every 6 hours (Max daily mg/ day)	
69	Peritonitis:	Intraperitoneal: continuous: LD: 250 mg/liter of dialysate MD: 50 mg/liter	
Immune globulin (IVIG)	Guillain-Ba (ITP):	rre syndrome/ immune thrombocytopenia	Comments: - May cause shock,
Blood Product Derivative)		IV: 1000 mg/kg/dose once daily for 2 days, or 400 mg/kg/dose once daily for 5 days	tachycardia, respirato- ry distress - Use hospital preset order
	Kawasaki c	lisease:	
		IV: 2000 mg/kg as single dose with 10 days of disease onset	
	Acute Disse	eminated Encephalomyelitis (ADEM):	
		IV 1000 mg/kg/day once/day for 2 days	
	Myocarditis	S.	
		limited date, IV 2000mg/kg single dose	
Insulin Regular	Infants, chi	dren and adolescents:	Comments:
Antidiabetic Agent	DKA	continuous IV infusion: 0.05 – 0.1 units/kg/ hour titrate to desired effect (concentration 50 unit/ 50ml)	May cause hypoglycemia
Ipratropium	Bronchosp	asm, wheezing, Asthma:	
Anticholinergic Agent	infants: Nebulizatio hours	n: 0.125 – 0.25 mg (125 -250 mcg) every 4	
		n: 0.25 – 0.5 mg (250 – 500 mcg) every 20 3 doses then as needed every 6 – 8 hours	

Iron	Iron deficie	ncy anemia:	Comments:	
	3 – 6 mg el	emental iron/kg/day divided every 8 – 24 hours	 May cause consti- pation, dark stools, epigastric pain May administer with food if GI upset occurs Do not administer with milk or milk products 	
Kayexalate (sodi- um polystyrene) • Antidote, Hyperkalemia	P.O: 1 g/kg dose)	/dose every 6 hours as needed (Max: 15 g/	Comments: - May cause hypokalemia, hypomagnesemia and	
	Rectal: 1 g (Max. 30 –	/kg/dose every 2 – 6 hours as needed 50 g/dose)	 hypocalcemia Mixed with water 	
Ketamine	Sedation fo	or minor procedure:	Comments:	
 Sedative, Anesthetic 		IV: 0.5 – 2 mg/kg	 Increased blood pressure (BP) 	
		Induction dose: 1 – 2 mg/kg as part of rapid sequence sedation	 Increase oral secre- tion (risk of airway 	
	Sedation:		obstruction & apnea)	
		continuous IV infusion: 5 – 20 mcg/kg/minute, start at lower dose and titrate to effect		
Labetalol	Hypertension:			
 Alpha/Beta Adrenergic Blocker 	P.O:	initial: 1 – 3 mg/kg/day in two divided doses (Max daily dose: 10 – 12 mg/kg/day up to 1200 mg/day)		
	IV:	intermittent bolus: 0.2 – 1 mg/kg/dose (Max dose: 40 mg)		
	Hypertension emergency:			
	contin- uous IV infusion:	0.25 – 3 mg/kg/hour initiate at lower end of rang and titrate up slowly		
Lactulose	Constipatio	pn:		
Laxative	P.O:	1 – 2 g/kg/day (1.5 to 3 ml/kg/day) once or twice daily (Max daily dose: 60 ml/day)		

Levetiracetam • Anticonvulsant	Partial onse	et seizures:	Comments: - Increase dosage gradually every 2 weeks as tolerated (7 - 10 mg till reach recommended dose) - May cause neutro- penia, leukopenia, thrombocytopenia and pancytopenia
	Infants 1 to <6 months:	P.O / IV: initial: 7 mg/kg/dose twice daily, usual dose: 21 mg/kg/dose twice daily	
69	Infants>6 months and children < 4 years:	P.O / IV initial: 10 mg/kg/dose twice daily, usual dose: 25 mg/kg/dose twice daily	
	Children ≥ 4 years:	P.O / IV: initial: 10 mg/kg/dose twice daily, usual dose: 30 mg/kg/dose twice daily. (Max daily dose: 3000 mg/day)	
	Status epile	epticus:	
	followed by	ng/kg/dose, (Max. dose 2500 mg / dose) / IV or P.O maintenance dosing: 30 – 60 mg/ ded twice daily	
Levothyroxine	Hypothyroi	dism (acquired or congenital):	Comments:
 Thyroid Product 	P.O:		- IV, IM dose (50 – 70%) of the oral dose
	1 to 3 months	10 – 15 mcg/kg once daily	 May cause hyper- tension, arrhythmias, palpitation and cardiac arrest May cause diarrhea and weight loss. May case behavior problems (includes aggression, agitation & anxiety)
	3 to 6 months	8 – 10 mcg/kg once daily	
	6 to 12 months	6 – 8 mcg/kg once	
	1 – 12 years	4 – 6 mcg/kg once daily	
	>12 years	2 - 3 mcg/kg once daily	
Lidocaine	Anesthesia	: local injection (children & adolescent):	Comments:
 Antiarrhythmic Agent, Class Ib 		5 mg/kg/dose (Max. 300 mg/dose)	 Patients with reduced hepatic function or
		mic: Pulseless Ventricular Tachycardia (VTAC), stant ventricular fibrillation(VF)	decreased hepatic blood flow (CHF, postcardiac surgery) should receive ½ the usual loading dose with maximum main- tenance dose of (20 mcg/kg/minute) - For cutaneous injection: use < 2% concentration
		IV, I.O: LD: 1 mg/kg/dose over 2 minutes follow with continuous IV infusion	
		Continuous IV infusion: 20 – 50 mcg/kg/ minute	
		E.T: 2 – 3 mg/kg/dose flush with 5 ml NS and follow with 5 assisted manual ventilations.	

Linezolid	General do	sing, susceptible infection:	Comments:
 Antibiotic, Oxazolidinone 		P.O, IV: 10 mg/kg/dose every 8 hours (Max dose: 600 mg)	 May cause anemia, leukopenia, pancyto- penia, eosinophilia,
	Tuberculos	is, multidrug-resistant:	neutropenia and
		P.O: 10 – 12 mg/kg/dose twice daily (Max dose: 600 mg)	 thrombocytopenia May increased serum bilirubin
Lorazepam Benzodiazepine	Anxiety/ sedation	P.O, IV: 0.05 – 0.1 mg/kg/dose (Max dose: 4 mg/dose) every 4 to 8 hours	Comments: - May cause respiratory
	Status epileptics:	IV: 0.05 – 0.1 mg/kg (Max dose: 4 mg/dose) administer over 2 -5 minutes, may repeat in 5 to 15 minutes if needed	depression, sedation - Flumazenil is the antidote
Magnesium oxide	Hypomagn	esemia:	Comments:
Electrolyte Supplement	P.O:	children: 10 – 20 mg/kg elemental magnesi- um /dose, 1 – 4 times /day	 400 mg tablet = magnesium 20 mEq = elemental magnesium 242 mg May cause diarrhea (dose related)
Magnesium sulfate	Hypomagn	esemia:	Comments: - May cause diarrhea with high doses - May cause hypo- tension - 1 g of magnesium sulfate ~100 mg elemental magnesium = 8 mEa elemental
Electrolyte Supplement	IV. I.O:	Dose expressed as magnesium sulfate 25 – 50 mg/kg/dose (0.1 – 0.2 mmol/kg/ dose) every 6 hours for 2 to 3 doses (Max dose:2 g/dose) Dose expressed as elemental magnesium: IV: 2.5 – 5 mg/kg/dose every 6 hours for 2 to 3 doses	
	P.O:	elemental magnesium: 0.2 – 0.4 meq/ kg/ dose every 6 – 8 hours	magnesium = 4 mmol of magnesium
	Status Asth	imaticus:	-
		25 – 50 mg/kg/dose as single dose (Max. 2g/ dose)	
	Torsade de	pointes:	
		25 – 50 mg/kg/dose (Max. 2 g/ dose)	
Mannitol Diuretic, Osmotic	High ICP:		Comments:
	IV:	0.25 – 1 g/kg/dose infused over 20 – 30 min. PRN (Max dose: 2 g/kg/dose), repeat as needed every 4 – 6 hours	 Contraindicted in patient with severe pulmonary edema or congestion Use with caution in patient with underly- ing renal disease May cause extravasation
	Should NO mOsm/kg	T be given if serum osmolality more than 320	

Meropenem	General do	sing susceptible infection:	Comments:
Antibiotic, Carbapenem	IV:	20 – 40 mg/kg /dose every 8 hours (Max dose: 1000 mg/dose)	 Adjust dose in renal impairment
	Meningitis	/ severe infection:	
619	40 mg/kg/o	dose every 8 hours (Max dose: 2000 mg/dose)	
Methylene Blue	Methemog	lobinemia:	Comments:
- Antidote	I.O, IV	1 – 2 mg/kg; may be repeated every 30 to 60 minutes.	 Use with caution in G6PD deficiency or renal insufficiency. May cause nausea, vomiting, dizziness headache, diaphore- sis, stained skin and abdominal pain. Cause blue-green discoloration urine and feces.
Methylpredni-	Asthma, ex	acerbation:	Comments: - May cause hyperten- sion, hyperglycemia and adrenal sup- pression
solone Corticosteroid	IV:	LD: 2 mg/kg/dose (once), then 0.5 – 1 mg/kg/ dose every 6 hours (Max. dose 60 mg/day)	
	Anti-inflam	matory/immunosuppressive:	
	IV:	0.5 – 1.7 mg/kg/day in divided doses every 6 – 12 hours	 May increase tacroli- mus level In rare cases can
	Pulse therapy:		cause anaphylactic reaction
	IV:	15 – 30 mg/kg/dose or 600 – 1000 mg/ m2/dose once daily for 3 days (Max dose: 1000 mg)	 Use with caution in patients with GI disease
Metoclopramide	Postpyloric	feeding tube placement:	Comments: - May cause extrap- yramidal effect and tardive dyskinesia - Administer on empty stomach at least 30 minutes prior to food
 Antiemetic, Prokinetic Agent 	IV:	< 6 years: 0.1 mg/kg as single dose 6 to 14 years: 2.5 – 5 mg as single dose	
	Gastroeso	phageal reflux:	
69	IV, P.O:	0.1 – 0.2 mg/kg/dose every 6 to 8 hours (Max dose: 10 mg)	

Metolazone	Edema refi	ractory:	Comments:	
Diuretic	P.O:	0.2 – 0.4 mg/kg/day divided every 12 – 24 hours (in combination with furosemide) (Max. adult dose: 20 mg)	 Contraindicated in patients with anuria or hepatic coma or hypersensitivity to sulfonamides May cause hypo- kalemia and/or hyponatremia 	
Metronidazole	General do	sing, susceptible infection:	Comments:	
 Antibiotic, Anaerobic 	P.O:	30 – 50 mg/kg/day divided every 8 hours (Max daily dose: 2250 mg/day)	 Use with caution in patients with end stage renal disease 	
	IV:	22 – 40 mg/kg/day divided every 8 hours (Max daily dose: 1500 mg/day)	 May cause aseptic meningitis , leukope- 	
	Clostridiun	n difficile diarrhea:	nia and thrombocy- topenia	
69	P.O:	30 – 50 mg/kg/day in divided doses 4 times daily (Max daily dose: 2000 mg/day)		
Midazolam	Sedation, anxiolytic:		Comments:	
 Benzodiaz- epine 		intermittent IV: initial: 0.05 - 0.1mg/kg/dose	 May cause hypo- tension, respiratory 	
	Sedation, r	nechanically ventilated patient:	depression - Flumazenil is the	
		continuous infusion: 0.5 – 2 mcg/kg/minute Maximum dose: 6 mcg/kg /minute (titrate to desired clinical response)	antidote	
	Status epil	epticus:		
69		Continuous infusion: 1 – 24 mcg/kg/minute. begin at lower end of range and titrate to lowest effective dose		
Milrinone • Phosphodi- esterase - 3 Enzyme Inhibitor		g/kg administered over 15 minutes followed by us infusion of 0.25 – 1 mcg/kg/ minute titrate ect	Comments: - May cause hypo- tension (you could omit LD in case of hypotention) - Use with caution in patient with renal impairment - Reduce loading dose or omit in patients at risk for hypotension	

Morphine	Analgesia,	moderate to severe:	Comments:	
 Analgesic, Narcotic 	P.O:	Infant < 6 month: 0.1 mg/kg/dose every 3 – 4 hour	 May cause CNS and respiratory depression May cause nausea, 	
69		Infants >6 month and children: 0.2 – 0.5 mg/kg/dose every 3 – 4 hours (Max. dose: 15 – 20 mg)	vomiting, constipa- tion, hypotension, bradycardia and	
	IM, IV:	initial: 0.05 – 0.2 mg/kg/dose every 2 – 4 hours as needed Maximum dose: infant 2mg/dose, 1 – 6 years 4 mg/dose 7 -12 years 8 mg/dose adolescent 10 mg/dose	 urinary retention May cause pruritus (may be dose related), rash and urticarial Naloxone is the antidote 	
		s IV infusion: g/kg/hours, titrate dose to effect		
Naloxone	Opioid into	xication:	Comments: - May cause arrhyth- mias, ventricular fibrillation, pulmonary	
Antidote for Narcotic Agonists	IV, I.O:	0.1 mg/kg/dose repeat every 2 – 3 minutes if needed (Max dose: 2 mg/dose)		
	Reversal of respiratory depression from therapeutic opi- oid dosing: IV: 0.001 – 0.01 mg/kg/dose, repeated every 2 – 3 min. if needed.		edema, hepatotoxicity and opiate withdrawal symptoms	
Nifedipine	Hypertensive urgency:		Comments:	
Calcium Chan- nel Blocker, Dihydropyri- dine	P.O:	0.1 – 0.25 mg/kg/dose, Max single dose: 10 mg, (Max daily dose: 2 mg/kg/day) may repeat if needed every 4 – 6 hours	 May cause flushing, palpitation, tachycar- dia and hypotension 	
Nitroglycerin	Dose: continuous IV infusion:		Comments:	
Vasodilator, Antianginal, Antihyperten- sive Agent	minute eve	– 0.5 mcg/kg/minute, titrate by 0.5 mcg/kg/ ry 3 to 5 minutes as needed 10 mcg/kg/minute)	 Use with caution in severe renal impairment Tolerance to hymody namic and antiangine effects can develop within 24 to 48 hours of continuous use May cause methemo globinemia, thrombo cytopenia 	

Nitroprusside	Continuou	s IV infusion:	Comments:
Antihypertensive Agent, Vasodilator		0.3 – 0.5 mcg/kg/minute (Max dose: 10 mcg/ kg/minute) titrate to effect	 May cause cyanide toxicity and thiocy- anate toxicity can occur in patients with renal impairment or those on prolonged infusions (i.e., > 3 mcg/kg/minute for > 72 hours) May cause hypo- tension Use with caution in patients with elevated intracranial pressure, hepatic and renal impairment
Norepinephrine	Continuou	s IV infusion:	
Alpha – Adren- ergic Agonist		initial: 0.05 – 0.1mcg/kg/minute, titrate to desired effect (Max dose: 2mcg/kg/minute)	
Nystatin Antifungal Agent	Infant dose: 200,000 – 400,000 units/dose every 6 hours		Comments: - May cause diarrhea, nausea, stomach pain and vomiting - Give half of the dose to each side of the mouth.
	Child & adult: 400,000 – 600,000 unit/dose every 6 hours		
Octreotide	Chylothorax:		Comments:
Somatostatine, Analog		continuous IV infusion: 0.3 – 10 mcg/kg/hour titrate to response	 May cause hyperg- lycemia May cause tachy-
	Esophagea	al varices/GI bleeding:	phylaxis
69		1 – 2 mcg/kg initial IV bolus followed by 1 – 2 mcg/kg/hour Taper dose by 50% every 12 hours when no active bleeding occurs for 24 hours	
	Persistent	hyperinsulinemic:	
		SubQ: 2 – 10 mcg/kg/day divided 3 – 4 times daily (Max daily dose: 40 mcg/kg/day)	
Omeprazole	GERD:	1	Comments:
Proton Pump Inhibitor	P.O:	0.7 – 3.3 mg/kg/day every 12 -24 hours (Max daily dose: 20 mg/day)	 Administer all doses before meals May cause nausea,
	IV:	0.5 – 1 mg/kg/day divided every 12 -24 hours	vomiting and diarrhea

Ondansetron	Gastroente	eritis, acute; treatme	nt:	Comments:	
Antiemetic	Infants and children: IV: 0.15 – 0.3 mg/kg/dose			 May cause Q – T prologation Use with caution in 	
	Infants and	d children ≥ 6 month	s ≥ 8 kg:	patients with hepatic	
	P.O	8 – 15 kg: 2 mg/do >15 to 30 kg: 4 mg >30 kg: 8 mg/dose	/dose once	impairment	
	Chemothe	rapy induced nause	a and vomiting:		
	P.O, IV:	dose: 16 mg/dose,	every 4 – 8 hours (Max 3 doses total), administer es before the start chemo-		
	Cyclic vom	niting syndrome:			
	IV:		lose every 4 – 6 hours o 3 doses (Max dose: 16		
Oseltamivir	Treatment:		PO:	Comments:	
Antiviral Agent		infants 1 to 8 mont daily	hs: 3 mg/kg/dose twice	 Treatment should ideally begin within 48 hours however 	
2.0		9 to 11 months: 3.5	5 mg/kg/dose twice daily	initiation after 48	
	Fixed dosi	ng:	PO:	hours may decrease mortality or duration of illness	
		< 3 months: 12 mg	twice daily for 5 days		
		3 to 5 months: 20 r	ng twice daily for 5 days		
		6 to 11 months: 25	mg twice daily for 5 days		
		Children: ≤ 15 kg: days)	30 mg twice daily (for 5		
		> 15 to 23 kg: 45 m	ng twice daily (for 5 days)		
		> 23 to 40 kg: 60 m	ng twice daily (for 5 days)		
		> 40 kg: 75 mg twi	ce daily (for 5 days)	_	
	Prophylaxi	s: PO:			
		3 to 11 months: 3	mg/kg/dose once daily		
	Fixed dosi	ng: PO:		_	
		3 to 5 months: 20 r	mg once daily		
		6 to 11 months: 25	mg once daily	_	
		Children: ≤ 15 kg: 3	30 mg once daily	_	
		> 15 to 23 kg: 45 m	ng once daily		
		23 to ≤ 40 kg: 60 m	ng once daily	-	
		> 40 kg: 75 mg ond	ce daily		

Palivizumab: (SYNAGIS) • Monoclonal Antibody	RSV preve	ntion:	Comments: - May cause rash, pain rhinitis, cough, wheeze - May cause diarrhea, vomiting and increase liver enzyme
		IM: 15 mg/kg once monthly throughout RSV season (Max: 5 doses/ season)	
Pantoprazole:Proton Pump	GERD:	1	
Inhibitor		Children <5 years: 0.6 - 1.2mg/kg/day	
	P.O:	Children ≥5 years: ≥ 15 to <40 kg: 20 mg once daily for up to 8 weeks >40 kg: 40 mg once daily for up to 8 weeks	
	IV:	Gastric acid suppression: IV: 0.8 – 1.6 mg/kg once daily. Max: 80mg	
Penicillin G • Antibiotic, Penicillin	Mild to moderate infections:	IM, IV: 100,000 – 150,000 units/kg/day divided doses every 6 hours (Max daily dose: 8 million units/day)	Comments: - May cause urticarial and anaphylaxis - May cause interstitial nephritis and hemolyt ic anemia
RS	Severe infections:	IM, IV: 200,000 – 300,000 units/kg/day in divided doses every 4 – 6 hours (Max daily dose: 24 million units/day)	
	GBS (group B strepto- coccus):	infant IV 450,000 – 500,000 unit/kg/day divided every 6 hours	
	Menin- gococcal disease:	infant, children & adolescent: IV: 300,000 unit/ kg/day divided every 4 – 6 hours (Max. 12 million unit/day)	
PENTobarbital	Reduction	of elevated ICP:	Comments:
P		5mg/kg every 4-6 hours (Other dosing options available)	 Tapering rate by 0.5 mg/kg every 12 hours May cause respiratory
Gg		epticus refractory to standard therapy (pento- ma with strongly recommended continuous ling):	depression, hypo- tension
		IV, LD: 5 – 15 mg/kg; maintenance infusion: initial: 1mg/kg/hour, may increase up to 5 mg/kg/hour.	

Phenobarbital	Status epile	epticus:	Comments:
Barbiturate, Anticonvulsant	IV:	initial: 15 -20 mg/kg (Max dose: 1 g) may repeat once after 10 – 15 minutes if needed (Max total dose: 40 mg/kg)	 Start maintenance dose 12 hours after loading dose May cause respiratory
60	Maintenano 12 hours	ee dose: P.O, IV: 3 – 6 mg/kg/day divided every	depression, hypo- tension - Monitor phenobarbital therapeutic level (15 – 40 mcg/ml = 65 – 172 mcmol/L)
Phentolamine	Extravasati	on of vasopressor:	Comments:
 Alpha – adren- ergic Blocking Agent, Antidote – Extravasation 	diluting 5 m	ea with 1 ml of 0.5 – 1 mg/ml solution (made by 1g in 10 ml of NS) within 12 hours of extravasa- t exceed 0.1 – 0.2 mg/kg/dose or 5 mg total)	 Inject 1 ml (in 5 divided doses of 0.2 ml around site of extravasation)
Phenylephrine	Hypotensic	n low cardiac output:	Comments:
Alpha – Adren- ergic Agonist	IV bolus:	5 – 20 mcg/kg/dose every 10 to 15 minute (Max: 500mcg/dose)	 May cause peripheral and visceral vasocon- striction
	Contin- uous IV infusion:	initial: 0.1 – 0.5 mcg/kg/minute, titrate to desired response (Max: 2 mcg/kg/minute)	 May cause extrava- sation
Phenytoin	Status epilepticus:		Comments: - Start the maintenance therapy 12 hours after
Anticonvulsant, Antiarrhythmic	LD: IV: 15 – 20 mg/kg/dose (Max: 1 g)		
Agent, Class IB	in 2 – 3 dos Usual rang	te dose: P.O, IV: initial: 5 mg/kg/day divided tes a: 4 − 8 mg/kg/day divided in 2 − 3 doses dose: 300 mg/day)	 the loading dose Free (unbound) phenytoin serum concentrations should be monitored closely in patients with renal/ hepatic disease or in those with hypoalbu- minemia Monitor phenytoin therapeutic level (10 – 20 mcg/ml = 40 – 79 mcmol/L) May cause lethargy, nystagmus, hirsutism, gingival hyperpla- sia and cardiac arrhythmia Rate of intravenous administration 0.5 mg/ kg/minute

Phosphate	Hypophos	phatemia:	Comments:
Electrolyte Supplement	IV:	0.16 – 0.36 mmol/kg over 6 hours, repeat dose as needed.	 Order as sodium or potassium phosphate Potassium phosphate:
Gjð	P.O:	1 -2 mmol/kg/day divided every 6 – 12 hours	 Potassium 4.4 mEq and phosphorus 3 mmol per mL) Sodium phosphate: (Phosphate 3 mmol/ mL and sodium 4 mEq/ml)
Piperacillin/Tazo-	General do	sing, susceptible infection:	Comments:
 Antibiotic, Penicillin) 		100mg/kg/dose every 8 hours (Max dose: 4 g/dose)	 May cause thrombo- cytopenia Adjust dose in renal
(dose based on	Cystic fibro	sis, pseudomonal lung infection:	impairment
piperacillin		100 mg/kg/dose every 6 hours (Max daily dose: 18 - 24 g/day)	
Potassium	Hypokalen	ia:	Comments: - Infusion rate: 0.3 – 0.5 meq/kg/hour - Continuous cardiac monitoring recom- mended for rate> 0.5
Chloride Electrolyte Supplement 	P.O:	2 – 5 meq/kg/day in divided doses every 2 – 8 hours not to exceed 1 -2 meq/Kg/dose (In the presence of severe hypokalemia see electrolyte guidelines for potassium IV bolus)	
69	Intermit- tent IV:	(must be diluted prior to administration) 0.5 – 1 meq/kg/dose (Max dose: 40 meq), repeated as needed based on lab values	meq/kg/hour - Rapid intravenous administration may cause cardiac
	For more i	nformation see hypokalemia guideline	arrhythmias - Monitor potassium level frequently
Procainamide	Antiarrhyth	mic:	
 Antiarrhythmic agent, Class I-A 	IM:	children and adolescents: 20 – 30mg/kg/day divided every 4 – 6 hours, Max daily dose: 4g/day	
6	IV, I.O:	infants, children and adolescents: LD: 10 – 15mg/kg over 30 to 60 minutes, Max dose range in adult (1000 – 1500 mg). MD: continuous infusion: 20 – 80 mcg/kg/ minute; Max daily dose: 2000mg/24hours	

Prednisolone	Asthma:			Comments:
Corticosteroid	P.O:	1 – 2 mg/kg/day in times/day (Max: 60	divided doses 1 to 2 mg/day)	 May cause hyperten- sion, hyperglycemia, gastrointestinal
	Anti – inflammatory or immunosuppressive:		hemorrhage	
	P.O:	0.1 – 2 mg/kg/day i times /day	n divided doses 1 to 4	
Propofol General Anes- 	Induction/ LD:	IV: 1 – 3 mg/kg/ dose		Comments: - May cause hypertri-
thetic	Mainte- nance:	IV infusion: 0.5 – 4 mg/kg/hours		glyceridemia - May cause arrhyth- mia, bradycardia and
	not exce	se propofol related infusion syndrome (Do ad 4mg /kg /hour for 24 hour). /kg /minute = 1.2 mg /kg /hour)		hypotension - Contraindication: in patient with hypersen- sitivity to eggs, egg products, soybeans, or soy products
PropranololBeta Adrener- gic Blocker	Hyperten- sion:	doses titrate dose t	P.O: initial: 1 – 2 mg/kg/day divided in 2 to 3 doses titrate dose to effect (Max: 4 mg/kg/ day) (up to 600 mg/day)	
	Tachyar- rhythmias:	P.O: initial: 0.5 – 1 mg/kg/day in divided dos- es every 6 – 8 hours; titrate dosage upward every 3 to 5 days Usual daily dose: 2 – 4 mg/kg/day (Max: 16 mg/kg/day (60 mg/ day)) IV: 0.1 – 0.15 mg/kg over 10 minutes may repeat every 6 to 8 hours (Max. infant dose 1mg/dose, Max. child / adolescent 3mg/dose)		 May cause brad- ycardia, hypoten- sion, heart block, bronchospasm and hypoglycemia Use with caution in patient with hepatic impairment
Prostaglandin E1 See Alprostadil				

Protamine	1 mg of pro	otamine neutraliz	es 100 units of heparin	Comments:	
 Antidote, Heparin 	1 mg protamine neutralizes 1 mg (100 units) LMWH (enoxaparin Sub Q) (Max dose: 50 mg)			 Protamine dosage is determined by the most recent dosage 	
	• Regular	heparin:		of heparin or low mo- lecular weight heparin (LMWH)	
		Heparin I	V overdose		
		Time Since Last Heparin Dose (Minunte) Dose (Minunte) Dose of Protamine (mg) To Neutralize 100 Units of hypotensive		 Too rapid administra- tion can cause severe hypotensive and anaphylactoid – like 	
		<30	1	 reaction Infusion rate should not exceed 5 mg/ 	
		30-60	0.5-0.75		
	6	60-120	0.375-0.5	minute.	
		>120	0.25-0.375		
	Heparin SubQ overdose:	1 – 1.5 mg prota	amine/ 100 unit heparin		
	 LMWH over- dose: 	within the last 4 mg LMWH (100 Second dose of units) LMWH m	lose has been administered hours, use 1 mg protamine/1 units) f 0.5 mg protamine/ 1 mg (100 ay be given if APTT remains hours after the first dose		
Ranitidine	Infants, Ch	nfants, Children, and Adolescents ≤16 years:		Comments:	
Histamine H2 Antagonist	Duodenal o	or gastric ulcer/ E	Frosive esophagitis/ GERD:	- May cause head- aches, mild gastroin-	
	Treatment: P.O:	4 to 10 mg/kg/day divided twice daily (Max daily dose: 300 mg/day)		testinal disturbances	
	Mainte- nance:	2 to 4 mg/kg/day once daily (Max daily dose: 150 mg/day)			
	IV:	2 to 4 mg/kg/day divided every 6 to 8 hours (Max dose: 50 mg/dose)			
	GI bleed or	stress ulcer; pro	pphylaxis:		
	IV:	Infants: 2 to 6 m hours (Max: 50 mg/do	ng/kg/day divided every 8 ose)		
			dolescents: 3 to 6 mg/kg/day hours (Max daily dose: 300		
Rasburicase	Hyperurice	mia:			
Uric Acid Lower- ing Agent	IV:	0.05 – 0.2 mg/k 5 days	g/dose once daily for up to		

Rifampin	Antitubercu	Ilosis:	Comments:
Antibiotic, Antitubercular Agent	P.O, IV:	10 – 20 mg/kg/day given once daily (Max dose: 600 mg)	 May cause throm- bocytopenia and hyperbilirubinemia
	Staphyloco	occus infection:	 Use with caution
	P.O, IV:	15 mg/kg/day divided every 12 hours (Must use in combination with systemic antistaphy- lococcal antibiotic) (Max dose: 600 mg)	in patient with liver impairment - Causes red/ orange discoloration of body secretion (Urine, feces, saliva, tears and CSF fluid)
Risperidone:	Delirium:		Comments:
Antipsychotic	Children < 5years:	P.O: initial: 0.1 – 0.2 mg once daily at bedtime	 May cause anticholin- ergic effects (constipation, urinary)
	Children > 5years and ado- lescents:	P.O: 0.2 – 0.5 mg once daily at bedtime, may titrate to lowest effective dose every 1 – 2 days	retention, blurred vision)
	Maximum daily dose	dependent upon patient weight: <20kg: 1mg/day, 20 to 45kg: 2.5mg/day, >45kg: 3mg/day	
Rocuronium	Rapid sequ	ience intubation:	Comments:
(Neuromuscular Blocker Agent, Nondepolarizing)	IV:	0.6 – 1.2 mg/kg/dose	 Use with caution in patients with hepatic impairment
	Intermit- tent IV dosing:	0.075 to 0.15 mg/kg; repeat as needed	 Use with caution with patient with pulmo- nary hypertension
	Contin- uous IV infusion:	5 to 12 mcg/kg/minute (0.42 to 0.72 mg/ kg/hour)	

Salbutamol	Asthma, ad	cute exacerbation: Oral inhalation:	Comments:
 Beta2-Adren- ergic Agonist, Bronchodilator 		Inhalation aerosol (metered dose inhaler): 90 mcg/puff: 4 to 8 puffs every 20 minutes for 3 doses then every 1 to 4 hour	 Round the dose to the nearest dosage form May cause tachycar- dia, hypokalemia and
	Nebulizatio	n, Intermittent:	hyperglycemia
69		0.15 mg/kg (minimum dose: 2.5 mg) every 20 minutes for 3 doses then 0.15 to 0.3 mg/kg not to exceed 10 mg every 1 to 4 hours	 Use with caution in patient with renal impairment
	Nebulizatio	n, Continuous:	
		0.3 – 0.5 mg/kg/hour, higher doses of 3 mg/ kg/hour (Max dose: 15mg/hour)	
	Continuous	s IV infusion:	
		0.5 – 10 mcg/kg/minute	
	Hyperkaler	nia:	
		Oral inhalation: Nebulization: 10 mg/dose or 0.3 to 0.5 mg/kg/dose	
Sildenafil	Pulmonary	hypertension:	Comments:
 Phosphodi- esterase Type – 5 (PDE5) Inhibitor 	P.O:	Initial: 0.25 – 0.5 mg/kg/dose every 8 hours; titrate as needed; (Max dose: 1 mg/kg/dose every 8 hours)	 May cause flushing, hypotension and increase liver enzyme Use with caution in
	Children ar	nd Adolescents:	patient with hepatic
		8 to 20 kg: 10 mg three times daily	impairment - Use with caution in
69		>20 kg to 45 kg: 20 mg three times daily (Max recommended dose: 20 mg 3 times daily)	patient with renal impairment - Avoid sudden cessa- tion of sildenafil may result in an exacerba- tion of PAH
Sodium Bicar-	Metabolic	acidosis:	Comments:
 Alkaliniz- ing Agent, Electrolyte Supplement 	gases and HCO3- (ml	ould be based on the following formula if blood pH measurements are available: Eq) = 0.3 x weight (kg) x base deficit (mEq/L) mEq) = 0.5 x weight (kg) x [24 - serum HCO3-	 May cause hyper- natremia, severe pulmonary edema and hypocalcemia May cause extrava- sation
	Usual dose:	1 – 4 meq/kg/dose IV infusion over 4-8 hours; subsequent doses should be based on patient's acid-base status	 For IV infusion dilute in a dextrose solution to maximum concen- tration (0.5 meq/ml)

Sodium Benzoate	Infants and	Children:	Comments:	
 Hyperam- monemia Agent 	Initial loading dose:	P.O, IV: 0.25 g/kg/dose over 90 minutes	 May cause hyper- ammonemia and hypokalemia Use with caution in 	
	Followed by	P.O: 0.25 g/kg/day divided every 6-8 hours OR IV continuous infusion: 0.25 g/kg over 24 hours	patient with Reye's syndrome and hyper- bilirubinemia - Do not repeat loading dose	
Sodium Chloride	Hyponatrer	nia:		
Electrolyte Supplement		e the necessary dose: Dose (mEq sodium) = asma sodium (mEq/L) – actual sodium (mEq/L)] ght (kg)	(sodium content of	
		ce dose: - 4 mmol /kg/day divided 2 – 8 hours -2 mmole /kg/day divided 2 – 8 hours	513mEq/L) - (0.9% sodium chlo- ride Na content 154 mEq/L)	
	3% hypertonic solution		- Pretreatment the hy-	
		Increased intracranial pressure (ICP): continuous IV infusion: 0.1 – 1 ml/kg/hours titrated to maintain ICP and/or 6 – 10 ml/kg/dose over 20 min. (Max. bolus dose 250 ml/dose) (serum osmolality not exceed 360 mOsmol/L)	 pertonic resolutation with a bronchodilator is recommended to prevent potential bronchospasm Prefer to infuse the Hypertonic saline through central line through cent	
		Nebulization: Bronchiolitis, viral: inhaled: 4 ml inhaled every 2 hours for 3 doses followed by every 4 – 6 hours		
		Bronchodilator diluent: 1 – 3 ml to dilute bronchodilator solution in nebulizer before administration		
	Cystic fibro	sis: 7 % solution: 4 ml inhaled twice daily		
Sodium Polysty- rene sulfonate	See Kayexalate			
Spironolactone • Diuretic, Potas-	Diuretic, hy	pertension:	Comments: - May cause hyper-	
Diuretic, Potas- sium Sparing		1 – 4 mg/kg/day or 60 mg/m2/day in divided doses every 6 -12 hours (Max: 100 mg/day)	 May cause hyper- kalemia, acidosis, nausea and vomiting 	

Sotalol • Antiarrhythmic Agent, Class II, III, Beta-Adren- ergic Blocker	crease dos allow 3 day steady-stat Max: 10 m	y/kg/day divided every 8 hours; if needed, in- age gradually by 1 to 2 mg/kg/day increments; is between dosage increments to achieve new te g/kg/day (if no limiting side effects occur) do adult doses (Max adult daily dose: 320 mg/	Comments: - Monitor clinical response, heart rate, and QTc intervals - It is not necessary to increase to target dosage if desired clinical effect has been achieved at a lower dosage
Succinylcholine (Neuromuscular	Endotrache cents:	eal intubation: infants, children and adoles-	Comments: - May cause hypoten-
Blocker Agent, Depolarizing)	IV	Infants: 2 – 3 mg/kg/dose Children: 1 – 2 mg/kg/dose Adolescents: 1 – 1.5 mg/kg/dose	sion, bradycardia, arrhythmia malignant hyperthermia and hyperkalemia
	IM	4 – 5 mg/kg/dose (Max. dose 150 mg/dose)	 Contraindicated with previous history of malignant hyperther- mia severe burns, spinal cord injury, neuromuscular dis- ease or myopathies and hyperkalemia.
Thiopentone Short – acting 	Intermit- tent dose:	IV: 1 – 4 mg/kg/dose	Comments: - May cause hypo-
Barbiturate	Contin- uous IV infusion:	1 mg/kg/ hour and increase as needed up to a maximum of 8mg/kg/hour.	tension - High alkaline pH will cause tissue necrosis upon extravasation - Use with caution in patient with hepatic and renal impairment
Topiramate Anticonvulsant,		asms/ Anticonvulsant, adjunctive therapy/ neralized tonic – clonic seizures:	Comments: - Use with caution in
Miscellaneous	P.O	Initial: 1 to 3 mg/kg/day divided every 12 – 24 hours (Max: 25 mg/dose), titrate every week in 1 to 3 mg/kg/day increments as tolerated until seizures controlled	patient with hepatic and renal impairment - May cause cognitive dysfunction - May cause metabolic
	Usual maintenance (P.O): 5 to 9 mg/kg/day in 2 divided doses Max daily dose: 50 mg/kg/day should		acidosis - Don't discontinue abruptly, therapy should be withdrawn gradually

Tramadol	Moderate t	o severe pain: P.O:	Comments:	
Analgesic, Opioid		Immediate release tablet or liquid: 1 to 2 mg/kg/dose every 4 to 6 hours; (Maximum single dose: 100 mg) (Maximum total daily dose is the lesser of: 8 mg/kg/day or 400 mg/day)	 Use with caution in patient with hepatic and renal impairment 	
Tranexamic Acid	Intermitten	t dose:	Comments:	
Antifibrinolytic Agent, Hemo- static Agent		IV: 10 mg/kg immediately before procedure, then 10 mg/kg/dose 3 to 4 times daily; may be used for 2 to 8 days	- May cause Venous and arterial throm- bosis or thromboem- bolism	
	Infusion rate:		- May cause Hypo-	
G B	In children 5 to 40 kg:		tension (with rapid IV injection)	
		IV: Loading dose: 6.4 mg/kg over 5 minutes followed by a weight-adjusted continuous infusion in the range of 2 to 3.1 mg/kg/hour, up to 10 mg/kg/hour as needed.		
Tromethamine	Metabolic	acidosis:	Comment: - May cause respira- tory depression, hypoglycemia, and hyperkalemia - May cause extrava- sation	
(THAM) • Alkalinizing Agent	Dose (mL) (mEq/L) x 1 Usual rang	dosage based upon base deficit: of THAM = body weight (kg) x base deficit .1* e: 1 - 2 mEq/kg/dose; Maximum dose: 15 hours (15 mmol/kg/24 hours)		
69	Each mL o	f THAM = 0.3 nmol= 36 mg= 0.3 mEq	 Use with caution in patients with renal impairment; reduce dose and monitor pH carefully 	
Terbutaline	Asthma:		Comments:	
Beta2 Agonist	Contin- uous IV infusion:	LD: 2 – 10 mcg/kg, followed by 0.1 – 0.4 mcg/kg/minute depending upon the clinical response. Titrate in increment of 0.1 – 0.2 mcg/kg/min Q 30 minute. (Max: 10 mcg/kg/minute)	 May cause tachycar- dia, hypokalemia and hyperglycemia 	

Ursodcoxycholic Acid • Gallstone		nutrition induce cholestasis/improvement in metabolism of essential fatty acid in cystic	Comments: - May cause GI upset, biliary obstruction and
Dissolution Agent		30 mg/kg/day in 3 divided doses	increase liver enzyme
, igoni	Biliary atresia:	10 – 20 mg/kg/day in 2 - 3 divided dose	
	Pruritis second- ary to cholesta- sis:	P.O. 15 -20 mg/kg/day OD or BID up to 30 mg/kg/day	
Valproic Acid	Seizures di	sorders:	Comments:
Anticonvulsant	P.O:	Initial: 10 to 15 mg/kg/day in 1 to 3 divided doses; increase by 5 to 10 mg/kg/day at weekly intervals	- Children receiving more than 1 anticon- vulsant may require doses up to 100
		Maintenance: 30 to 60 mg/kg/day in 2 to 3 divided dose.	mg/kg/day in 3 to 4 divided doses
	Status epilepticus; refractory:		 Total daily IV dose is equivalent to the total
	IV:	LD: Initial: 20 to 40 mg/kg	daily oral dose but IV dose should be divid- ed every 6 hours - May cause hepato- toxicity - Therapeutic level 50- 100 mcg/ml (350- 690 micromoles/L)
Vancomycin	General do	sing, susceptible infection:	Comments:
 Antibiotic, Glycopeptide 	Mild to moderate infection:	IV: 40 – 45 mg/kg/day divided every 6 – 8 hours (Max daily dose: 2000 mg/day)	 May cause red man syndrome with rapid IV administration Measure trough
69	Menin- gitis/ Severe infection:	IV: 45 – 60 mg/kg/day divided every 6 – 8 hours (Max daily dose: 4000 mg/day)	level before 3rd or 4th dose, but earlier if there is renal dys- function.
	C. difficile	associated diarrhea (CDAD):	 Therapeutic serum trough level 10 – 15
		P.O: 40 mg/kg/day divided every 6 – 8 hours for 7 to 10 days , (Max daily dose: 2000 mg/ day)	mcg/ml for mild to moderate infection; 15 -20 mcg/ml if the MIC >1
		/intrventricular ervative free preparation):	 Use with caution in patients with renal
		5 – 20 mg/day	impairment

Vasopressin	Diabetes in	sipidus:	Comments:
 Antidiuretic Hormone Analog 		Continuous IV infusion: initial: 0.5 milliunits/ kg/hour (0.0005 units/kg/hour) Max: 10 milliunits/kg/hour (0.01 units/kg/hour)	 May cause extrava- sation Use with caution in patients with renal
	Vasodilator	y shock with hypotension:	impairment
		continuous IV infusion: 0.17 – 8 milliunits/kg/ minute (0.01 – 0.48 units/kg/ hour)	
Vitamin B6 (Pyri-	Pyridoxine	dependent seizures treatment:	Comments:
doxine)Vitamin, Water Soluble	P.O, IM, IV:	initial: 50 – 100 mg one dose	 Don't discontinue abruptly, therapy should be withdrawn
	P.O:	Maintenance: 50 – 200 mg/day (30 mg/kg/day)	gradually - May cause GI distur- bance, sedation and folic acid deficiency - May cause seizure (following very large IV doses)
Vitamin K (Phy- tonadione)	Vitamin K deficiency: (prevention, supplement & pro- longed INR):		Comments: - May cause hyperbili-
Vitamin, Fat Soluble	P.O, IV, SubQ, IM:	2 – 5 mg once daily (max: 10 mg/dose)	 rubinemia May cause anaphy- lactic reaction
Voriconazole	Treatment:		Comments:
Antifungal Agent		LD: 9 mg/kg/dose every 12 hours for 2 doses	 Use with caution in patients with hepatic
	P.O, IV:	MD: 9 mg/kg/dose every 12 hours (Max single dose: 350 mg)	and renal impairment - QT interval Prolon- gation has been
		LD: (if baseline INR 1 -1.3)0.2 mg/kg (max dose: 10 mg)	associated with voriconazole - May cause
	P.O:	MD: 0.1 mg/kg/day	hypokalemia and hypomagnesemia
		Usual range: 0.0534 mg/kg/day	nypoinagnesernia

ElectrolyteS

Management:	
Obtain 12 lead ECG.	ECG Changes: (sensitivity of ECG to detect hyperkalemia is no very reliable)
If K level < 6.5 and no ECG changes:	Arran Agentalion Paulity Int. Material Agentative Manualities
 a. Discontinue exogenous sources of K (IV& oral) b. Discontinue medications that limit its excretion (e.g. Spironolactone). c. Na Polystyrene Sulfonate (Kayexalate): 1 g/kg orally or rectally in sorbitol solution d. Follow up of level every 4-6 hours with continuous ECG monitoring till normalized . 	Weit 0.1.4.1 million?
If K level > 6.5 and/or ECG changes:	
 a. Glucose (0.5 - 1g/kg) + regular insulin (0.2 unit / min. b. Consider Inhaled B2 agonist 2.5 mg for child <2 	
 c. Consider NaHCO3 1 – 2 mEq/kg over 5 – 10 min Definitive removal of plasma K*: a. Kayexalate (alternative: calcium resin) 1 g/kg ora b. Consider Loop (furcosemide) or Thiazide diuretic c. Consider dialysis in setting of renal failure or remeasures 	nutes ally or rectally s to increase renal excretion
Definitive removal of plasma K*: a. Kayexalate (alternative: calcium resin) 1 g/kg orr b. Consider Loop (furosemide) or Thiazide diuretic: c. Consider dialysis in setting of renal failure or re measures	nutes ally or rectally s to increase renal excretion
Definitive removal of plasma K*: a. Kayexalate (alternative: calcium resin) 1 g/kg ora b. Consider Loop (furosemide) or Thiazide diuretic c. Consider dialysis in setting of renal failure or re-	nutes ally or rectally s to increase renal excretion

Use IV route If level is less than 2.5 mEq/l or with symptomatic hypokalemia

Use bolus if symptomatic or with high risk of arrhythmias

Rate of infusion: Preferred not to exceed 0.5 meq/kg/hr (may rarely use up to Max Rate 1 meq/k/hr) Peripheral vs central: PIV max. 60 meq/l while CVL max 120 meq/l (Lexicom)

K-Level	Oral	IV
0.0.05	Increase oral intake or	Increase KCI in IVF or
3.0 – 3.5 mEq/l	0.5 mEq/kg/dose max 20 mEq/dose Can Be repeated every 6 – 8 hours	0.25mEq/kg KCl over 1 hour
2.5 – 3.0 mEq/l	1 mEq/kg/dose max 20 mEq/dose Can Be repeated every 6 – 8 hours	0.5mEq/kg KCl over 2 hours
2.0 – 2.5 mEq/l	2 mEq/kg/dose max 20 mEq/dose Can Be repeated every 6 – 8 hours	0.75mEq/kg KCl over 3 hours
< 2.0 mEq/l or Hypokalemia induced paralysis or Hypokalemia induced ECG changes		0.5 mEq/kg over 60 minutes

Hypernatremia (Na > 145 mEq/l):

Hypernatremia with dehydration/hypovolemia:

- Give isotonic (0.9 NS) fluid bolus for resuscitation
- Replacement therapy (e.g. gastroenteritis):
 - a. Estimate total fluid needed: Maintenance, deficit (dehydration %) and ongoing loss
 - b. Do not start with 1/4 NS hypotonic fluid (use 0.9 NS or 1/2 NS till proper fluid identified)
 - c. Estimate extra free water needed: 4ml x weight (kg) x desired Na change
 - d. Correct hypernatremia slowly (brain edema risk)
 - I. Chronic hypernatremia (> 24hours): decrease plasma Na* by 0.5 mEq/l every hour (10 12 mEq/l/24h).
 - II. Usually 4ml/kg of free water drop Na by 1mEq/I
 - e. Replace free water via oral/NG tube whenever possible.
 - f. IV free water administration is prohibited.
 - g. Measure serum and urine electrolytes and monitor serum Na drop frequently (every 2 4 hrs)
 - h. Hourly neurologic examination
- ► For Diabetes Insipidus (DI):
 - a. Free water replacement as per ongoing loss (monitor U.O closely)
 - b. Consider IV Desmopressin or Vasopressin to control rapid water loss and hypernatremia

Hypernatremia with Euovolemia or Hypervolemia:

- a. Withdraw Na* source and consider adding free water
- b. For severe compromised patients add furosemide and free water
- c. Usually 4ml/kg of free water drop Na by 1mEq/l
- d. Patient with renal failure, consider dialysis.

Hyponatremia:

Hyponatremia with dehydration/hypovolemia:

- a. Give isotonic (0.9 NS) fluid bolus for resuscitation
- b. If presenting with active seizure: 6 ml/kg of 3% NaCl over 20 30 minutes.
- c. Correct fluid and Na⁺ deficits
- d. Total Na deficit (mEq/l) can be calculated as = (desired Na plasma Na) x (Wt x 0.6)
- e. Generally, Na⁺ deficit replaced at rate of 0.5 mEq/hour
- f. Determine the type and amount of IVF replacement (maintenance and deficit of Na* and water)
- g. Follow hydration and biochemical parameters 4 6 hourly.
- h. Replacement of ongoing salt losses is paramount.

Hyponatremia with Euvolemia or hypervolemia:

- a. Treat symptomatic hyponatremia with infusion of hypertonic saline
- b. Restrict water only or in combination with hypertonic NaCl and a loop diuretic.
- c. Correct the cause of hyponatremia
- In asymptomatic child, the target rate of rise should not exceed 0.5 1 mEq/l/hour to avoid central pontine lysis demyelination

Hypercalcemia:	
Treatment:	ECG Changes:
 Restore intravascular volume and enhance renal excretion by administration of normal saline at 2 to 3 X maintenance fluid rate. If adequately hydrated and Ca⁺⁺ do not decrease, administer loop diuretics. Consider Calcitonin and bisphosphonates as adjunct treatment in severe hypercalcemia Consider hemodialysis using a low Ca⁺⁺ dialysate in severe case in which hydration and medication fail. 	 Shortened QT interval Ventricular dysrhythmias

Hypocalcemia:			
Treatment:	ECG Changes:		
 Acute symptomatic hypocalcemia (i.e. tetany, muscle twitching, carpopedal spasm, laryngospasm, or seizure): 	 Prolongation of QT interval Non-specific ST – T wave changes Rarely cause ventricular arrhythmias 		
 a. Calcium Gluconate bolus (100-200 mg/kg to a maximum of 3 gm, preferred through central line) over 10 - 20 minutes. b. Then start a continuous infusion of Ca Gluconate at 10 - 30 mg/kg/h to maintain adequate Ca⁺⁺ levels. Rate of infusion then titrated based on serial Ca⁺⁺ measurements Once symptoms resolve or in asymptomatic patient who can take enteral Ca⁺⁺, start on 50mg/kg body weight/24h of elemental Ca⁺⁺ into 3 or 4 doses. In hypocalcemic patient with hypomagnesemia, correct mg with IV mg sulfate or oral mg oxide. In patient with concurrent hyperphosphatemia, correct levated phosphate by phosphate i Ca-phosphate product exceeds 80 mg2/dl2 = 6.4 mmol2/L2) 	HIPPERALEMAA		

Hypomagnesaemia:	
Treatment:	ECG Changes:
 Symptomatic patient or asymptomatic patient with Mg level < 1mg/dl (< 0.41mmol/l) require IV replacement with Mg sulfate at dose of 25 – 50 mg/kg (0.1 – 0.2 mMol) as a slow IV infusion over 2 hours. Dose should be repeated every 6 hours until level stabilize. Check Mg level 2 hours after infusion. Treat mild to moderate hypomagnesemia of 	 Secondary hypokalemia can present with nonspecific T wave changes, u waves, a prolonged QT interval, widening of QRS complex, prolongation of PR interval and ventricular arrhythmias. Hypomagnesemia predispose to cardiac dysrhythmias, particularly Torsade De Pointes.
 1 - 1.5 mg/dl (0.41 - 0.61 mmol/l) with oral supplementation at doses of 20 - 40 mg/kg of elemental mg per dose. (Max. dose 400 mg in 24 hours). ▶ Follow PALS recommendations for Torsade De Pointes. 	WWWWWWWWW

Hyperphosphatemia (look for aluminum phosphate dosage)

- · Review dietary intake, medications, and renal function.
- · Volume expansion with normal saline does improve excretion.
- · Phosphate chelators to decrease phosphate absorption.
- · Consider dialysis in renal failure patient with severe hyperphosphatemia.

Hypophosphatemia:

Treatment:

- Patients with serum phosphate > 2.2mg/dl (> 0.71mMol/l): Increase intake of milk.
- Patients with serum phosphate levels < 1.5mg/dl (< 0.5mMol/l) and/or symptomatic hypophosphatemia: treatment with IV phosphate preferred:
 - Asymptomatic severe hypophosphatemia (< 1.5mg/dl) give 2.5mg/kg (0.08 mMol) of elemental phosphorus over 6 hours.
 - b. Symptomatic patient, give 5 mg/kg (0.16 mMol) of elemental phosphorus over 6 hours.
 - N.B: Do not exceed the maximum dose of 0.24 mMol/kg/dose.
 - N.B: Check serum K, Ca, phosphate and Mg 2 hours after completing infusion.

Septic shock in Children

0 - 5 minutes	Recognition Decreased level of consciousness Persistent tachycardia Decreased urine output Hypotension (late sign)	Cold shock: cold & prolonged capillary refill time Warm shock: warm & brisk capillary refill	 Airway, Breathing, Circulation support (as per PALS guidelines(Provide 100% O2 using non- rebreather mask Keep the patient NPO. Establish 2 peripheral IV. If IV not achieved within 5 minutes insert IO (take blood sample/culture if possible) Correct hypoglycemia & hypocalcemia Start fluid boluses
5 - 15 minutes	 kg). Repeat as needer Use small boluse (hepatomegaly, card crepitation) Administer 1st dose control 	s for cardiac patient iomegaly, gallop, basal	Initial therapeutic endpoint: Capillary refill of ≤2 seconds & Warm extremities (in cold shock() Normal blood pressure for age. Normal pulses with no difference between peripheral and central Achieve threshold heart rate for age. Urine output ≥1 mL/kg/hr. Normal mental status.
15 - 60 minutes	or epinephrine (0.0 peripheral IV or IO. Consider elective ini ketamine (1-2 mg/kg) of bradycardia) (0.02n If still in shock: Titrate up epinepl	p to 10 mcg/kg/min) 15-0.3 mcg/kg/min) in tubation: suggest using ±atropine (if there is risk ng/kg) (IV/IO). nrine for cold shock, warm shock (through	Initial Lab and radiology request: Blood Gases, Glucose, CBC, Electrolyte, Urea & Creatinine, Lactate, Coagulation profile, Albumin, Liver Function Tests, Type & Cross match Blood C/S, Urine analysis & C/S Consider LP (for stable patients with suspicion of meningitis(CX-Ray
> 60 minutes	random cortisol level • Keep hemoglobin abc • Target mixed venous : • Monitor Lactate level. • Early control of infecti • Consider stress ulcer • Strict in and out (insee • Consider echocardiog	one (2mg/kg loading the if possible(vve 10 gm/dl. saturation. ≥70%. on source. prophylaxis. t folly's catheter) yram for sick patients on h	n 1 mg/kg Q6hr) for persistent shock (send igh inotropic/vasopressor support. ysfunction and cold shock

Pediatric Vital Sign Normal Ranges					
Age Group	Heart Rate	Respiratory Rate	Systolic BP	Weight in Kg	
Newborn	120-160	30-50	50-70	2-3	
Infant (1-12 months)	80-140	20-30	70-100	4-10	
Toddler (1-3 yrs)	80-130	20-30	80-110	10-14	
Preschooler (3-5 yrs)	80-120	20-30	80-110	14-18	
School Age (6-12 yrs)	70-110	20-30	80-120	20-42	
Adolescent (≥a3 yrs)	55-105	12-20	110-120	>50	

Age	Systolic BP
<1 month	>60 mm/Hg
Imonth-1year	>70 mmHg
1 year-10 years	(2*apr)+70
>10 years	>90 mmHg

Status epilepticus in Children

Recognition and initial stabilization	Investigations
 Maintain A, B, C + Neurologic exam Give oxygen by cannula or mask Connect to cardiorespiratory monitor Connect to pulse oximeter (check O2 Sat) Establish IV access Prepare for possible intubation Correct any electrolyte abnormalities (hypoglycemia, hyponatremia, hypocalcemiaetc) 	Check bed side glucose Point of care blood gases (including Na, iCa) Send lab: Electrolyte, Mg, Ca, Po4, CBC, Urea & Creatinine, LFT. Consider when clinically indicated: Anticonvulsant drug level Toxicology, metabolic screen. Blood and urine cultures Lumbar Puncture (if no contraindication) CT/MRI brain

Start anticonvulsant treatment after 5 minute of seizure activity (Consider pre-arrival seizure duration)

Initial Therapy Phase is Benzodiazepine	
□ If there is IV/IO:	□ If No IV/IO:
 Lorazepam 0.1 mg/kg/dose, max: 4 mg/dose OR Midazolam 0.1-0.2 mg/kg Max 10mg) Both of them can be repeated once If both not available use: Diazepam (0.15-0.2 mg/kg/dose, max: 10 mg/dose) 	 IM midazolam (one dose) 0.2mg/kg If not available use: Rectal diazepam 0.2 – 0.5 mg/kg maximum 20mg.

Second Therapy Phase choose either options 1 or 2			
(The patient must be on cardiorespiratory monitor)			
Option 1: choose one of the following:		Option 2:	
 Intravenous fosphenytoin (20 mg/kg/dose) over 5 to 10 minutes or Phenytoin (20 mg/kg/dose) slowly over 30 minutes OR Intravenous valproic acid (40 mg/kg, max: 3000 mg/ dose, single dose OR Intravenous levetiracetam (20-60 mg/kg, max: 2500 mg/dose, single dose 		Intravenous phenobarbital 20 mg/kg/dose single dose	

Third Therapy Phase

- Call PICU and pediatric neurology
 Use the alternative choice of second therapy phase

 $\ensuremath{\ensuremath{\texttt{x}}}$ if you choose option1 in previous phase go for option 2 now and vice versa.

Refractory status epilepticus:	Midazolam infusion:
 Request for continuous EEG look for clinical or subclinical seizure, o non-convulsive status epilepticus (NCSE) Consider insertion of central venous line Be ready for intubation Monitor vital sign and check fo arrhythmias 	 Increase by 2 every 10-15 min PRN (with seizure) up to 24 mcg/kg/min Common side effects:

40 - 60 minutes

Management of Status Asthmaticus in Children

Definition: Status asthmaticus is an asthma attack that fails to respond to initial doses of nebulized B2agonist, anticholinergic agents and systemic corticosteroid and requires admission to the hospital for aggressive therapy

Be careful from asthma mimickers (e.g. foreign body, heart failure, pneumonia, airway diseases, aspiration...etc.)

Initial Management of Asthma		Simplified Ventolin dose	
► O2 to maintain O2 Saturation >90% ► Keep NPO		< 5yrs	2.5 mg
 Short acting beta agonist: Nebulized Albuterol (Salbutamol): 0.15-0.3 mg/kg for 3 doses back to back mixed in 3-5 ml 0.9% saline (15-20 minutes each) 		≥ 5 yrs 5 mg	
		minimum 2.5 mg, max 10 mg (wean with improvement)	
 Nebulized Ipratropium Bromide (Atrovent): 0.5 mg (mix with above Ventolin) 			
 Steroids: Methylprednisolone IV loading 2mg/kg then 2mg/kg/ day (max 60 mg/day) divided every 6 hrs for 5 days 	H	ternative cortico ydrocotisone IV 00 mg) every 6 h	5 mg/kg/dose (maximum

High risk groups	Recommended investigations
 Previous PICU admission (with or without intubation) Patient on three or more classes of asthma medications Repeated ER presentation/hospitalization for asthma Poor compliance with asthma medications (Caution: 25% of serious asthma present as 1st attack, & up to 75% of mortalities as not 	 CBC: high WBC with neutrophilia could be stress or asthma medications effect Chest radiograph: rule out pneumothorax, pneumonia, or aspiration of foreign body Blood gases: Normal/high CO2 may indicate worsening asthma exacerbation Lactate: Metabolic acidosis with high lactate may occur following B2 agonist treatment

If failing to responds to above (Status Asthmaticus)	IV fluid
 Notify PICU Continuous short acting beta agonist 	Fluid PAL
Nebulized Albuterol (Salbutamol): 0.5 mg/kg/hr through an infusion pump to deliver at the desired rate to the nebulizing	 IV ma if no
chamber. (e.g. 5 mg/ Kg body weight of Ventolin mixed with 200ml 0.9% saline to run at rate of 20 ml/hr as nebulizer)	(patient) due
If not available, continue back-to-back Salbutamol at the same	incr
dose above ▶ Ipratropium bromide nebulization 0.5 mg 4-6 hourly for 24 hr	losse Avoid
 May increase methylprednisolone dose to 4 mg/kg/day (divided Q 6 hrs) 	prec ► Add
	- Auu

 Consider Magnesium Sulfate 25-50 mg/kg IV over 30 minutes (max 2 gm)

(patient should be on monitor, watch for hypotension, apnea)

10

- boluses if in shock (follow S guidelines)
- aintenance D5 0.9% Saline ot in shock
- its are usually dehydrated to poor oral intake and reased insensible fluid ies)
- d overhydrating as this may cipitate pulmonary edema.
- KCI 20 mmol/L post 1st void and if K <5 mmol/L

Monitoring: Check Electrolytes every 8-12 hrs Monitor closely serum potassium values, which may decrease because of use of β 2 receptor agonists.

If no adequate response, consider:

 MgSO4: 25 to 50 mg/kg/dose infused over 30 min(max 2 g), May repeat every 6 hrs for 24 hrs (consult PICU)

Short acting beta agonist, IV infusions:	Monitor:
Terbutaline infusion: Loading dose 10 mcg/kg IV over 10 Minutes.	 Heart rate
Initial infusion: 0.2 mcg/kg/min, increase by 0.1- 0.2 mcg/kg/min every 30	▶ BP
minutes	 Arrhythmias
(Maximum dose 10 mcg/kg/min) OR	 Potassium
 Salbutamol infusion: Initial 1 mcg/kg/min increase by 1 mcg/kg/min Q 15 	
minutes if needed (Maximum dose 10 mcg/kg/min)	

Theophylline, usually, is not recommended due to modest effect, difficult monitoring, and narrow toxic to therapeutic window

Failing to respond:				
Non-invasive ventilation:	& Permissive hypercapnia to maintain			
Can be used in awake, cooperative patient while awaiting the effect of medical therapy and to avoid intubation.	Intubation: should be done by an experienced physician by rapid sequence intubation.			
	morphine, atracurium) Complications (usually from	induction agent with Rocuronium (avoid air trapping): hypoxemia, hypotension, sema, and arrest (Prepare IV fluid bolus to ion).		
Indication for intubation:	 Severe hypoxemia 	 Deteriorating consciousness level 		
	 Respiratory arrest 	► Fatigue with rising CO2		

For mechanical ventilation settings, please refer to mechanical ventilation guidelines in this booklet.

Management of Severe traumatic brain injury in Children (with Glasgow Coma Scale (GCS)≤ 8)

	 Maintain ABC support (as per PALS guidelines) & Keep NPO Continuous cardiopulmonary monitor & pulse oximeter (O2 Sat) Use appropriate size Cervical-Collar 		Early Neurosurgical Consultation			
	Airway & Breathing		Investigations			
Initial Stabilization	 Jaw thrust NO head tilt to open the airway (? cervical injury). Secure the airway: Rapid Sequence Intubation (RSI) Suggested meds: Fentanyl & Rocuronium OR Etomidate & Rocuronium Maintain SpO2 > 92% and ≤ 98%. Maintain CO2: 35-40 mmHg 			 CBC Coagulation (INR, PTT), blood type and cross match Blood gases, Electrolyte, glucose, serum osmolality LFT, urea and creatinine 		
	Circulation				Images	
	IV access (IO if three attempt failed) If hypotensive: 20 ml/kg 0.9% Saline, repeat 3 times. Consider inotropes/vasopressors Consider PRBCs transfusion for massive bleeding or if required > 60ml/kg fluid boluses		 Brain Cervic 	est X ray in CT vical CT scan ervical spine clearance by neurosurgery)		
		_				
	 Elevate head of bed to 30o, in a midline, neutral position Control Ventilation: Target low normal PaCO2 (35- 				DO NOT ALLOW	Acceptable value
	mmHg)				Hypoxemia	O2 Sat >92%
ŝ	 Support circulation: Avoid hypotension (± arterial line) Consider intoropes/vasopressors to maintain BP 				Hypotension	Normal for age
					Hyperthermia	<37.5°C
	 Stress ulcer prophylaxis (e.g. ranitidine, ome Naso-gastric tube (Oro-Gastric if suspecting) 			Hyponatremia	Na >140	
oralidat di all'I Florective II le apres	skull fracture)* ► IVF 0.9% saline at maintenance (add Dextrose if				Hypo- Hyperglycemia	80-180 mg/dl
ž L	hypoglycemic) Strict In/Out 			High ICP	<20	
Dra	 Start feeding early if no contraindication 			Low CPP**	>50 (>40 infant)	
uaro	 Avoid constipation (use lactulose) Sodium: Maintain high normal Na (>140) 	Laboratory monitoring				
Stan	 Sedation: Start infusion (e.g. Fentanyl + Midazolam) Pre-suction (or any manipulation) sedation with IV Fentanyl PRN Maintain normal core temperature (Use cooling if needed). Consider neuromuscular blocking if shivering. Consider Seizure prophylaxis (phenytoin). 			Blood gases Q 6 hours & PRN Blood glucose Q 6 hours Electrolytes & osmolality Q 6 hours. BUN & Creatinine daily & PRN CBC & coagulation daily & PRN		

	If the ICP >20 mmHg for >5 min or for a rapidly rising ICP or patient is having clinical signs suggestive of high ICP	Clinical signs suggestive of high ICP (without IC monitoring):				
anagement	 Initial signs adgestive of high for without ICP monitoring): Drain CSF from EVD (if inserted) for 2-5 minutes then assess ICP Consider bolus sedation, analgesia and muscle relaxant (do not allow moving/coughing) Hyperventilation temporarily to PaCO2 30-35. Start hyperosmolar therapy: NaCl 3% 5-10 ml/kg over 5-10 mins Q2-6h PRN (Hold if serum osmolality***>360 mmol/L) OR Mannitol 0.5-1 g/kg over 20 minutes Q2-6h PRN (Hold if Serum osmolality>*320 mmol/L, and be cautious with diuretic effect and hypovolemia) 	 Decrease in GCS >2 from baseline New loss of pupil reactivity Development of pupil asymmetry New focal motor deficit Cushing's triad: Hypertension, Bradycardia, abnormal breathing 				
High ICP Management		 Start management Consult neurosurgery Consider Repeating CT scan at 48 hours and at 5th day to help guide your high ICP management duration 				
	Persistent elevated ICP (monitored or with clinical signs): Repeat CT scan					
	 Barbiturate coma: Thiopental or Phenobarbital Neurosurgical consultation for potential decompressive craniectomy. 					

* Base of skull fracture: CSF leak, Blood from the nose, raccoon eye, battle sign **CPP = MAP - ICP

***Osmolality = (Na x 2 + (BUN mg/dl /2.8) + (Glucose mg/dl /18)

Management of DKA in CHILDREN

	History:	Clinical findings:	Investigations:	Confirm DKA by:
RECOGNITION	 Polyuria Polydipsia Weight Loss Abdominal Pain Vomiting 	 Kussmaul Breathing (No wheezing or rhonchi) Lethargy Dehydration Confusion 	 STAT bedside glucose Blood gases, Electrolytes (Na, K, PO4, CI), Urea, Creatinine & Glucose Urine Ketone/Glucose 	 ▶ Ketonuria ▶ Glucose >200mg/dl (11.1 mmol/l(▶ pH <7.30 &/or Bicarbonate <15mmol/L

Patient in Shock: start resus	citation Patient not in Shock
 Support airway and breathing (Do not intubate for respirator only) Start 100% O2 O 0% O2 	Weight ≤20kg 7ml/kg Weight >20kg 5ml/ kg
 0.9% Saline, 10ml/Kg bolus over 1 hr If hypotensive: 10 ml/kg bolus over 5-10 min (repeat as needed to maintain normal BP) Consider Inotropes with poor response (? Sepsis) Consult PICU URGENTLY Once Stabilized: Go to post 1st hour management 	
	DO NOT Give Insulin bolus
	esponse DO NOT Give NaHCO3 (unless in life threatening conditions)
	1st hour DO NOT Give Unnecessary Fluid boluses
	DO NOT Give hypotonic fluid (0.225NS, 0.45NS)
	DO NOT Stop Insulin (unless hypoglycemic on D10%)
	DO NOT Insert Central Line (unless no line or on inotropes)

Lab work (if not done):

1ST HOUR MANAGEMENT

POST 1ST HOUR MANAGEMENT

► Lactate

- CBC/Differential
- ► HgA1C
- ▶ Serum osmolality
- Urine Analysis
 Cultures (urine & blood) if infection suspected

Ongoing lab (till resolution)

Blood glucoseQ1
 Blood gases.....

▶ Serum osmolality, Anion

gap & electrolytes.....Q4

▶ Urine for ketones, urea &

Creatinine

Decrease frequency if HCO3

significantly improved

Q2

012

Monitoring

- Cardiorespiratory monitoring
- Hourly neuro-signs (Pupillary reflex and GCS)
- Hourly vital signs
- Accurate fluids in & out hourly (patient should stay in positive fluid balance, review Q4 hrs)
- Total Fluid Intake includes ALL fluids (oral & IV)

Avoid drop of serum glucose >100mg/dl/hr (5.5 mmol/L/hr) & Avoid drop of effective osmolality*>10mmol/L Q4

Fluid Mar	nagement	Insulin	Potassium			
Type of fluid is Total Fluid according to w	Intake (TFI)	 Mix 50 unit of soluble insulin (Regular) in 50 ml 0.9% saline (Alternatively: mix 50 unit in 500 ml 0.9% saline bag) Insulin fluid volume to be included in the total rehydration calculation 	 KCI 40mEq/L once patient is voiding (unless K >5.5) Increase KCI to 60mEql/L if serum K <3.5 (Repeat K after 2 hours from the change) 			
Weight	TFI (ml/ kg/hr)	when using 500 ml bag ► 0.1 U/Kg/hr (standard dose)				
≤ 15 kg	5	► 0.05 U/kg/hr (newly	Phosphate			
> 15-35 kg	4	diagnosed or ≤ 5 Years or recently received	Do NOT Add PO4 (unless PO4			
> 35-50 kg	3	insulin injection)	<0.5mmol/L if so, add KPO4 20mmol/L			
> 50 kg	2		& maintain total K as before			
Dextrose						
 Add D5 to IVF if serum Glucose <250mg/dl Or with rapid drop of more than 100 mg/dl/hr Add D10 to IVF if serum glucose <180mg/dl 						

Always prepare the next fluid you are going to use

	DKA resolves if: pH >7.30, HCO3 >15	If acidosis is NOT improving:			
	& normal Anion gap (keep in mind hyperchloremic metabolic acidosis:	► Recheck the insulin preparation & infusion			
	persistent acidosis with normal anion gap)	► Consider hyperchloremic acidosis			
	After resolution:	► Consider sepsis. ► Revise the TFI.			
	 Start oral fluids (do not allow 	Clinical Criteria for Cerebral Edema			
	uncontrolled fluid) Start subcutaneous (SC) insulin Stop Insulin infusion 30minutes after SC insulin Start Diabetic diet If DKA corrected before the usual time of SC insulin, drop IVF to maintenance and drop insulin to 0.02U/Kg/hr & monitor Glucose Q2	Headache, Irritability, Decrease LOC, Vomiting, Bradycardia, Hypertension, apnea/irregular breathing, Arrhythmia, Pupillary changes			
		Treatment (refer to high ICP management)			
		Secure Airway			
		Neuro-protective measures Neurosurgical consultation			

Management Guidelines OF Adrenal Crisis IN CHILDREN

Causes		
Primary Adrenal Insufficiency ► Usually salt wasting (Hyponatremia, Hyperkalemia) ► Hyperpigmentation	Neonatal Presentation (Congenital)	Older Children)Acquired) ▶ Autoimmune ▶ Adrenoleukodystrophy
Secondary Adrenal Insufficiency Pituitary	Congenital	Acquired
Tertiary Adrenal Insufficiency ► Hypothalamus	 Septo-optic defect 	 Brain radiation Prolonged steroid use

When to	suspect it?	How to confirm it?
 Volume depletion Hypotension Hypoglycemia Hyponatremia Hyperkalemia 	 Hyperpigmentation Abdominal pain Fever ±Precocious puberty 	If the Patient Hemodynamically stable: Check Cortisol level baseline Give Cosyntropin(ACTH) 1 mcg IV Repeat Cortisol level after 30minutes, if Cortiso
 Volume depletion Hypotension Hypoglycemia Hyponatremia Hyperkalemia 	 Hyperpigmentation Abdominal pain Fever ±Precocious puberty 	level is <9mcg/dL this will confirm adrena Insufficiency.

Management					
Fluid Boluses: 20ml/kg Dextrose 5% Normal Saline up to 60ml/kg				Never delay the management if	
Treat Electrolyte imbalance if: ► Hyperkalemia: Refer to guidelines ► Hyponatremia: Refer to guidelines				adrenal crisis is suspected waiting for the results • Consult pediatric endocrinologist. • If did not improve consider other	
Steroid (Hydrocortisone) 50mg/m2 as bolus, then 50mg/m2 divided Q6hr for 24hr				differential diagnosis.	
Approximate Hydrocortisone Doses					
Infant	Infant 10mg Older Child 50mg				
Toddler	Toddler 25mg Adolescence 100mg				

CLABSI - Central Line Associated Blood Stream Infection

Definition*: A laboratory-confirmed bloodstream infection (LCBI) where central line (CL) was in place for >2 calendar days on the date of event, with day of device placement being Day 1, AND the line was also in place on the date of event or the day before.

Insertion Bundle	Daily Care Bundle
 Hand hygiene immediately before donning gloves. Using pre-filled central line cart. Full protective equipment: Patient covered by long/full body drape. Processor and assistant: sterile gown, sterile gloves, Mask and head cover Using Chlorhexidine* 2% with and alcohol 70% prior to prick. Appropriate catheter site selection. 	 Daily inspection of the catheter. Hand hygiene before palpating the insertion site. Port entry: maintained closed all the time: Change cover cap whenever the port is accessed. Swab the diaphragm of the port with alcohol before using for injection. CVC revised daily for possibility of removal. Access the CVC by sterile technique.

*Use a chlorhexidine based antiseptic for skin preparation in > 2 months & Povidine-iodine for children < 2 months.

Adhere to infection prevention practices at the time of CL insertion and document the compliance with aseptic technique.

Signs of local infections are redness, discharge & pain at the site of insertion

VAP - Ventilator Associated Pneumonia

Definition*: A pneumonia which develops while the patient is on mechanical ventilation for >2 calendar days on the date of event (with day of ventilator placement being Day 1), AND the ventilator was in place on the date of event or the day before.

VAP Prevention Strategies	Ventilation Related Strategies
 Adhere to hand-hygiene guidelines 	 Use non-invasive ventilation whenever possible
 Perform regular oral care with an antiseptic solution (chlorhexidine) 	 Minimize the duration of ventilation (daily weaning readiness assessment)
 Maintain patients in a semi-recumbent position (30-45 degree) 	 Avoid unplanned extubation and re intubation
 Avoid gastric over distention (NG tube) 	► Use a cuffed endotracheal tube with in-line suction
 Avoid routine H2 blockers (Ranitidine) and proton pump inhibitors (omeprazole) 	 Remove condensate from ventilatory circuit regularly (and keep the ventilator circuit closed)
 Maintain sterile technique during suctioning 	 Change the ventilatory circuit only when visibly soiled or malfunctioning
 Preferable to use only pre filled saline syringe during suctioning if available 	 When open suctioning or disconnecting, ensure that tube will be closed (e.g., directly connected to test lung and avoid touching anywhere in the bed)

CAUTI - Catheter-Associated Urinary Tract Infection

Definition*: A UTI where an indwelling urinary catheter was in place for >2 calendar days on the date of event, with day of device placement being Day 1, AND an indwelling urinary catheter was in place on the date of event or the day before.

Insertion Bundle	Daily Care Bundle
 Perform Hand Hygiene immediately before procedure. Maintain maximum Aseptic Technique. Use pre-prepared set. Use the smallest suitable catheter size. Competent personnel should do the procedure Secure the catheter properly. Maintain closed sterile drainage system. 	catheter. • Keep catheter continuously connected to th drainage system. • Daily Meatal Hygiene.

Try to use the indwelling urinary catheters only when it is absolutely indicated. Remove catheters as soon as possible.

*Centers for Disease Control and prevention (CDC) def. January 2016.

Note: For proper diagnosis of CLABSI, VAP, and CAUTI, please refer to the diagnostic criteria published and updated in CDC web site: www.cdc.gov

Antibiotic Lock Therapy Guidelines

Antibiotic lock therapy has been used in patients with infected but badly needed central venous catheters and can't be replaced easily (e.g. Total Parenteral Nutrition, chemotherapy or dialysis cath).

Caution:

- For Catheter Related Blood Stream Infection (CR-BSI), Antibiotic Lock Therapy (ALT) should not be used alone, but in conjunction with systemic antimicrobial therapy.
- Antibiotic Lock Therapy cannot be used when there are signs of exit site or tunnel infection as catheter salvage is the ultimate goal in this kind of therapy (consult ID service if in doubt).

Causative organisms:

- Coagulase Negative Staph is the most common
- ▶ Some gram negatives like E. coli, Klebsiella.
- ▶ Some gram positives like S. Aureus, Enterococcus.

Indication of Catheter Removal (antibiotic Lock is not recommended)

- CRBSI with staph aureus.
- ► CRBSI with pseudomonas, fungi or microbacteria species.
- Severe sepsis or hemodynamic instability.
- ▶ Persistent bacteremia despite 72 hours of proper antibiotic therapy (organism is susceptible).
- ► Complicated catheter infection (endocarditis, thrombophlebitis, and osteomyelitis).
- ► Tunnel infections, port abscesses, or exit site infections.

Standards Antibiotic Lock Solutions Concentration

Antibiotic	Dwell Times	Final concentration (mg/ mL) in Normal Saline	When Heparinized Antibiotic Lock Solution used: Concentration
Vancomycin	24 – 48 hours	5 mg/ml	1000 Heparin (Units/mL)
Cefazolin	24 – 72 hours	5 mg/ml	1000 Heparin (Units/mL)
Ceftazidime	8 – 12 hours	0.5 mg/ml	100 Heparin (Units/mL)
Gentamicin	12 – 24 hours	1 mg/ml	40 mg/mL citrate

Standards Antibiotic Lock Solutions Volume:

The final stock solution volume should be based on the length of the catheter but usually not more than 3mL

Duration of Therapy: Usually 7-14 days

Precautions:

▶ Hemodialysis Catheter: Lock solution to be renewed after every dialysis session.

 Heparin solution should be withdrawn and discarded at completion of dwell time and prior to initiating infusion or drawing blood.

Guidelines for Empirical Antimicrobial Therapy in Children

Common problem with prescribing antimicrobial to children:

- · Unnecessary administration of antimicrobials in viral illnesses
- · Inappropriate choice of empiric antibiotics
- · Lack of awareness of susceptibility patterns of common pathogens
- · Continuation of empiric therapy despite negative cultures in stable patients

Over prescribing can lead to:

- · Emergence of resistant bacteria
- · Super infection with opportunistic fungi
- · Increase the likelihood of adverse drug reaction.
- · Increases in the cost of healthcare

The following point should be considered when you apply these guidelines:

- · Change to specific therapy based on culture/sensitivity results and patient's clinical condition.
- In case of β-Lactam severe allergy, consult clinical pharmacist or consult ID service for alternative.
- Refer to formulary for Dosing of Antimicrobials and obtain cultures prior to starting antibiotics.
- · These guidelines will serve sick patient who requires admission and treatment as inpatients.
- · Special consideration will be given to unstable critically ill child (see below)

CENTRAL NERVOUS SYSTEM						
Indication	Suspected Pathogens	Antimicrobials of Choice	Alternatives/Comments			
	Meningitis					
Neonate (up to 4 wks)	Gr B Streptococcus, Gram negative Enteric Bacilli, Listeria	IV Ampicillin + IV Cefotaxime				
4 weeks – 3 months	Same as Neonates and Older Children	IV Ampicillin + IV Cefotaxime	Add Vancomycin in severely ill patients			
Older Children	S. pneumoniae, N. meningitides, H. influenzae	IV Ceftriaxone + IV Vancomycin	De-escalate according to sensitivity			

Encephalitis	Herpes Simplex Virus	IV Acyclovir		
If meningoencephalitis is suspected, refer to empiric antibiotics for Meningitis. Ensure sending HSV and other viruses PCR from CSF Samples				
V – P Shunt Related Infection	Coagulase-negative Staphylococci, Enteric gram negative bacilli	IV Vancomycin + IV Ceftazidime	Consider covering previous shunt infection pathogens (if known)	

Blood Stream Infections (Excluding Meningitis)					
Indication	Suspected Pathogens	Antimicrobials of Choice	Alternatives/Comments		
Septicemia or Bacterem	ia				
Neonates	Gr B Streptococcus, Gram negative Enteric Bacilli, Listeria, Enterococcus	IV Ampicillin + IV Gentamicin			
1 – 3 months	Same as Neonates and Older Children	IV Ampicillin + IV Cefotaxime	Add Vancomycin in very ill Patient		
> 3 months	S. pneumoniae, Meningococcus H. influenza, E. coli ± S. aureus	IV Ceftriaxone	Add Vancomycin in very ill patient.		
> 48 hours of Hospitalization	Consider hospital acquired like: P. aeruginosa, klebsiella pneumonia, staph aureus	IV Piperacillin- Tazobactam or Meropenem* + IV Vancomycin	Consider adding aminoglycoside in critically ill patient		
Sickle Cell Disease with sepsis	S. pneumoniae, H. influenzae Salmonella	IV Ceftriaxone + IV Vancomycin	For β-Lactam Allergy: Clindamycin + Ciprofloxacin		
	S. aureus, CONS, enteric gram-negative bacilli, Plus P.	Vancomycin + Ceftazidime	IV Vancomycin + IV Cefepime		
Aeruginosa and MDR Gram negative bacteria in immunocompromised patient.		Add aminoglycocides in severely ill patients and/or immunocompromised patients.			

*Consider the choice based on your own hospital organisms susceptibility patterns and antibiogram

**Add clindamycin for suspected cases of toxic shock syndrome

RESPIRATORY SYSTEM	1		
Indication	Suspected Pathogens	Antimicrobial of Choice	Alternatives/ Comments
Pneumonia	^	^ 	
Neonates	Group B Streptococcus, Gram negative Enteric Bacilli, Listeria	IV Ampicillin + IV Gentamicin	
Community – Acquired Pr	neumonia		
1 – 3 months	S. pneumoniae, C. trachomatis, B. pertussis, S. aureus, H. influenzae	IV Cefotaxime ± Macrolides (e.g. clarithromycin)	Obtain a viral NPA and consider Adding Oseltimavir.
3 months – 14 years			
Immunized	S. Pneumoniae, mycoplasma, staph aureus	IV Ampicillin ± Macrolides	IV Augmentin
Non-immunized	S. Pneumoniae, H. influenzae, Mycoplasma. P, S. Aureus,	IV Cefuroxime ± Macrolides	
Aspiration pneumonia	Anaerobes ± enteric gram negative	IV Augmentin	IV Clindamycin
Complicated Pneumonia			
Necrotizing pneumonia Para pneumonic effusion Empyema Pneumatocele Lung abscess.	S. pneumoniae, S. aureus, H. influenzae, S. pyogenes, C. pneumoniae, M.pneumoniae	IV Ceftriaxone + IV Clindamycin ± Macrolides	Consider IV Vancomycin + Piperacillin-Tazobactam ± Macrolides for sick PICU patient
Healthcare Associated Pr	neumonia		
Ventilated patient	Gram negative bacilli including P. aeruginosa, anaerobes, staph aureus	IV Piperacillin/ Tazobactam* ±IV Vancomycin ± IV Aminoglycocides	Cefepime + Clindamycin. (Add aminoglycocide if patient colonized with MDR organisms).
Not ventilated	Gram neg. bacilli Staph aureus	IV Piperacillin/ Tazobactam ±IV Vancomycin	

*Consider the choice based on your own hospital organisms susceptibility patterns and antibiogram

SKIN & SOFT TISSUE INFECTIONS				
Indication	Suspected Pathogens	Antimicrobial of Choice	Alternatives/Comments	
Cellulitis	S. aureus, Gr A Streptococcus	IV Cloxacillin or Cefazolin	IV Clindamycin	
Necrotizing Fasciitis	Gr A streptococcus, S. aureus, Polymicrobial, Clostridium spp.	IV Clindamycin + IV Cloxacillin	Consult ID on all cases consult Pediatric Surgery	

GASTROINTESTINAL SYSTEM					
Indication	Suspected Pathogens	Antimicrobial of Choice	Alternatives/ Comments		
Enterocolitis					
Neonates (NEC)	Enteric gram negative bacilli, Enterococcus spp., anaerobes	IV Ampicillin + IV Gentamicin ±Metronidazole			
C. Difficile – Associated	Clostridium. Difficile	Stop offending antibiotic + PO Metronidazole	PO Vancomycin NPO: IV Metronidazole		
Peritonitis					
Primary (spontaneous)	Strep. Pneumoniae, Gram negative bacilli	IV Ceftriaxone			
Secondary (i.e. post perforation)	Gram negative bacilli, anaerobes	IV Ampicillin + Gentamycin + Metronidazole	Consult ID		

URINARY SYSTEM							
Indication	Suspected Pathogens	Antimicrobial of Choice	Alternatives/Comments				
UTI	E. coli, Proteus spp.	IV Ceftriaxone	Amikacin if ESBL suspected				
Hospital Acquired (CA-UTI)	Gram negatives & gram Positives	Vancomycin & Piperacillin/Tazobactam	As per antimicrobial sensitivity testing				

Febrile neutropenic child need special consideration. Refer to specific guidelines or consult ID service. De – escalate to narrower spectrum antimicrobial as soon as susceptibility profile is available

	Nutrition IN picu						
Energy and protein	Energy and protein requirements for critically ill infants and children						
Age Energy Energy Protein Protein (in years) Kcal/kg/d Kcals/kg/d g/kg/d g/kg/d							
	Acute Phase (BMR**/paralysis/ sedation)	DRI* (BMR/activity/ new tissue)	DRI*	injury			
<1	55-45	107-79	1.5	3.0-2.0			
1-3	55-40	89-79	1.05	2.0-1.5			
4.6	50-40	81-62	0.95	2.0-1.5			
7-10	40-35	60-45	0.95	2.0-1.5			
11-18	35-25	47-30	0.85	2.0-1.5			

* DRI: Dietary Reference Intakes

** BMR: Basal Metabolic Rate

• Acute phase energy requirements reflect BMR, but maybe increased x 1.3-1.6 stress factor.

· Energy needs vary greatly especially during an acute phase of illness.

Total Energy Expenditure (TEE)

- The next step in determining a patient's energy/caloric needs is to calculate the total energy expenditure.
- Surgery, infection, trauma or other stresses to the body add to energy requirements, as does
 physical activity:
- TEE (kcal/day) = BEE x stress/activity factor. (BEE: Basal Energy Expenditure)

Stress or activity level	Stress Factor	Stress or activity level	Stress Factor	Stress or activity level	Stress Factor
Bed rest	1.1	Infection	1.3	Major trauma	1.7
Minor surgery	1.1 - 1.3	Fracture	1.3	Sepsis	1.7 - 1.9
Ambulatory	1.3	Major surgery	1.5	Burns	1.9 - 2.1

Suggested guidelines for initiation rate and advancement of enteral nutrition

Weight	Initiation rate	Advancement rate
<10 kg	Start at 1ml/kg/hr	Increase by 0.5 ml/kg every 4 hrs
>10 kg	Start at 0.5 ml/kg/hr	Increase by 0.5 ml/kg every 4 hrs

Common Formulas Available					
INFANT FORMULA: From 0 to 1	у.о				
CATEGORY	FORMULA (Examples not limited to)	ENERGY kcal/mL	Standard preparation for powder formula Scope/ml water		
Cow's Milk Based : Premature	Prenan	0.8	1scope/30ml		
Cow's Milk based	Similac Advance, s-26	0.68	1scope/60ml		
	Nan,ronalac		1scope/30ml		
Soy Based	Isomil	0.68	1scope/60ml		
Lactose free	Plemil plus LF, Al110	0.67	1scope/30ml		
High calorie Milk above 5kg	infantrini	1	liquid		
Protein & Fat Malabsorption Semielemntal formula	Neocate (free amino acid)	0.68	1scope/30ml		
Fat Malabsorption high in MCT Oil	Monogen	0.74	1scope/30ml		

PEDIATRIC FORMULAS 1-10 years (or above 7Kg)

CATE	GORY	FORMULA (Examples not limited to) ENERGY kcal/mL		Standard preparation for powder formula
Cow's Milk Based : Standard (oral or tube)		Pediasure 1 Resurse junier		liquid
Malabsorption	n semielemntal	Peptamin Jr.	1	1scope/30ml
Malabsorption		Peptamin	1	1scope/30ml
Age > 4 y.o	Cow's Milk Based	Fortisip	1	liquid
Above 10 yr.	Cow's Milk Based	Ensure	1	liquid

Modules to be added to the formula as needed

CATEGORY	FORMULA (Examples not limited to)	ENERGY kcal/mL	Standard preparation for powder formula Scope/ml water
Protein	Beneprotein	3.6 kcal/g 0.9 protein/g	As Pt. needs
Fat	Corn Oil MCT Oil	8.13 kcal/mL 7.7 kcal/mL	Min.1ml/100ml Max.4ml/100ml
Carbohydrate	Polycose Fantomalt	3.8 kcal/g 0.94 g CHO/g	As Pt. needs
Fat & carbohydrate	Doucal	4.9 kcal/g 0.73 g CHO/g 0.22 g Fat/g	As Pt. needs

Renal formula

CA	TEGORY	FORMULA (Examples not limited to)	ENERGY kcal/mL	Standard preparation for powder formula
	ow electrolyte om birth)	Renastart	1.0	1scope/30ml
Age > 4 y.o	Renal high protein (on dialysis)	Nepro HP Renal novasourse HDmax	1.8 1.8 1.5	Liquid
	Renal: Lower Protein &low electrolyte (pre dialysis)	Nepro LP	2	Liquid

Cautions:

 If patient is admitted on any special formula designed for special cases other than standard formulas please refer to dietician for further assistance.

NB: Infantrini should be used with caution in those < 5 kg.</p>

Metabolic Formula Composition Table: Values giver are per 1 gm unless otherwise indicated.

Family	lar Indentee	KorPresis CBD Fat	No K Plu. Implimpling	Can Ner (g)	Nati
	Advest PKU	440 0.17 0.51 0.317	1.00 5.75 4.00	400	PAE hus
	Adra (NU)	410-030-031-0.11	8.8113.767.48	80	750.0xx
	Adata MARTI	440 0.12 0.23 0.217	1.00 5.35 4.00	- 440	R.F. LEV, Vol. Soc
	defense all and a second address (CCCC)		218.748.639		Non-Rosential A.A. Box
	Anta For GA Top	11.0 10.0 10.0 10.0 10.0	8.0013291240	- 10	USA TIY be
	aders Types 1, 6, 1		1.00 8.75 6.00	-	PHEATTS.Soc
	dore & For Laurier dolta catellation		8.881379748		\$310 hos
	A mill option		941.642.9	20 ml #11	Protein line Contenne lantene StitueChenAg
	Alto Removative		88.037.748	-	CVLMIT for
	Ants SOLATES	410 0.00 0.01 0.01	8.8 11.79 Tall		REMERVALTING and OCIV free
Mod pt Too	A Press	3.3M. 8.417 6.4296.0007	3.79 536 5.29	1 pasket == (Cirges)	VAL RALLING

Pediatric NON-INVASIVE POSITIVE-PRESSUR	E VENTILATION
NPPV can augment oxygenation and ventilatio	n without insertion of an artificial airway
Continuous Positive Airway Pressure	BiPAP
CPAP increases the baseline system pressure (higher than atmospheric pressure) during spontaneous breathing, thus preventing collapse of distal small airways and alveoli.	One form of NPPV, bilevel positive airway pressure, augments ventilation by delivering pressurized air through a facial or nasal mask, nasal pillows, total face mask and nasopharyngeal
 Can be delivered invasively or non-invasively via nasal cannula, mask, tracheostomy, or endotracheal tubes. 	ET tube.Both the nasal mask and the face mask must be tight fitting to avoid leakage.
The respiratory rate and tidal volume (VT) are dependent on the patient's inspiratory effort	
Indications:	Clinical Signs of Improvement
NPPV found helpful in patients with: Asthma Chronic obstructive lung disease Neuromuscular disorders Obstructive sleep apnea Cystic fibrosis Upper airway obstruction Thoracic dysplasia. A means to avoid intubation in patient with mild to moderate acute respiratory insufficiency	NPPV can significantly improve: Respiratory rate Heart rate Work of breathing Decrease O2 requirement Signs of improvement or response which usually are seen within 2 hrs of trial
insufficiency In post extubations cases that is difficult to wean 	NPPV has been especially useful in previously health children with respiratory embarrassment due to muscle deconditioning following prolonged intubation.

Contra-indications:	Special Considerations (sedation use):
 NPPV is contraindicated in patients with: Rapidly progressive respiratory failure Hemodynamic instability Significant risk of aspiration Loss of protective airway reflexes or inability to clear copious oro-pharyngeal secretions Inability to properly fit the mask (e.g. facial trauma) 	 NPPV respiratory support requires the patient's cooperation, including a willingness to tolerate little or no sedation. Sedation may be used in some patients to enhance cooperation (e.g., midazolam, ketamine).

Initial setting				
Age Initial Setting				
Infants <12 months	Nasal CPAP should be attempted first. If CPAP does not provide adequate support, tracheal intubation is usually indicated.			
Toddlers 1-2 years	Ppeak: 8cm H2O; PEEP: 4cm H2O; FIO2: 1.0; ± backup rate appropriate for age and disease			
Children >2 years	Ppeak: 10cm H2O; PEEP: 5cm H2O; FIO2: 1.0; ± backup rate appropriate for age and disease			

Ppeak: peak inspiratory pressure; PEEP: positive end-expiratory pressure; FiO2: Fraction of Inspired O2.

Maximum settings & signs of failure of NIV

- · Effective delivery relies at least in part on the adequacy of the seal rather than the settings.
- Signs of failure of NIV: If a Ppeak >18-20cm H2O and PEEP >12-15cm H2O can be tolerated but does not decrease work of breathing or improve oxygenation sufficiency within 2-4 hrs, or if respiratory insufficiency is not improved, tracheal intubation is usually indicated.

Modes of NPPV:	
Spontaneous The patient triggers the inspiratory and expiratory pressure of rate and depth of breathing.	
Spontaneous/timed positive pressure:	Similar to the spontaneous mode, but machine breaths are delivered at a set frequency for patients who may be intermittently apneic.
Timed positive pressure:	Breaths are delivered at a set frequency, but the patient can still breathe spontaneously.
СРАР	A baseline system pressure is provided (usually 4 to 8cm H2O for children), but respiratory drive and effort must be maintained by the patient.

Note: Appropriate setting are based on the nature and severity of the patient's respiratory insufficiency. A word of caution: machines are often insufficiently sensitive to the respiratory efforts of small patients.

Advantages	disadvantages
 Decreased laryngeal trauma Decreased risk of ventilator-associated pneumonia or tracheitis Decreased the need for sedation and analgesia. The patient can talk, cough, cooperate with pulmonary toilet, and sip clear liquids (if a nasal mask is utilized) 	 The risk of skin breakdown over the nasal bridge An increased risk of aspiration due to gastric distention. Restriction of activity is often needed to maintain optimal mask placement. (Masks may not fit tightly and may not provide effective ventilation, particularly in small patients). Tracheal suctioning requires mask removal, which can lead to respiratory decompression.

PEDIATRIC Invasive MECHANICAL VENTILATION

Mechanical Ventilation Goals:	Avoid:
 Support Oxygenations (O2) Support Ventilation (CO2) Decrease Work of Breathing (WOB) Patient comfort and synchrony 	 Barotrauma (plateau pressure > 30) Volutrauma (tidal volume > 10-12 ml/kg) O2 toxicity (FiO2 > 0.5 -0.6) Atelec-trauma (stretching lung adjacent to atelectasis) Auto PEEP (air-trapping)

Please, ventilate gently and safely Normal values are not the ultimate goals in most PICU patients

Modes of Conventional Ventilation

Assist Control (AC):

It is a mode in which the ventilator provides a breath at:

- ► pre-set tidal volume- Vt (in volume control mode) or
- ► pre-set pressure-PIP (in pressure control mode)
- pre-set inspiratory time (Ti) in response to patient-initiated effort (patient trigger).
- pre-set volume/pressure at a pre-set frequency if patient does not trigger (time trigger).
- It is good starting mode in general but not for weaning.

Synchronized Intermittent Mandatory Ventilation (SIMV):

It is a mode of ventilation in which the patient can spontaneously breathe and in addition, receives a number of mandatory mechanical breaths with a pre-set Vt (or PIP), Ti and rate.


- Synchronization (SIMV) helps in keeping the mandatory breath in harmony with patient efforts.
- The ventilator delivers a pre-set volume/pressure at a pre-set frequency (IMV rate) with pre-set inspiratory time if patient does not trigger (time trigger).


A reasonable starting mode and It is good for weaning (interactive) and can be combined with Pressure Support mode.


Pressure Support Mode:

This is a spontaneous mode of positive pressure ventilation in which the ventilator delivers a pre-set pressure using a decelerating flow pattern and the patient determines his own inspiratory time and frequency.

- ▶ No back-up rate (apnea risk).
- PS is provided to counteract the ETT resistance and to assist patient efforts
- Spontaneous Breathing Trial (SBT) used before extubation is usually done using this mode.







Pressure Regulated Volume Control The most widely used mode in many PICUs as starting mode.

- It delivers the set tidal volume with decelerating flow pattern that decrease the pressure required to achieve the target Vt.
- During PRVC, the pressure and volume are regulated. Thus, all breaths are volume targeted, with pressure adjusted to reach that volume target.
- The ventilator gives several initial breaths at varying VTs that increase incrementally up to the set value.
- From this information, the ventilator computes the pressure target required to deliver the desired VT. Depending on the respiratory system compliance and resistance, the pressure associated with the tidal breath can vary over time.
- ▶ This mode can be used as standalone Assist Control or as SIMV- by different companies (e.g., PRVC mode (with PS).



This mode can be named differently +autoflow)

How to Initiate MV in PICU

There is no one optimal mode of ventilation for any particular disease state or one single optimal method of weaning from MV but these guidelines would work if properly followed in most cases. Understand pathophysiology to make smart choices and decide 1st what you want to achieve

- Choose the mode (AC or SIMV) based on patient condition and desired goals (need full control vs.
- interactive setting)
- Choose volume control, pressure control, or PRVC.

Recommended Initial Settings:

Tidal volume (Vt)	6 – 8cc/kg (per ideal body weight, IBW*)			
Frequency	30 – 40/min for infants, 20 – 30 for toddlers, 12 – 20 for older			
FiO2	1.0 (100%) and fast weaning to keep saturation >93%			
Inspiratory time (Ti) (keep I:E ratio of 1:2 to 1:3)	0.3 – 0.6 sec in infants 0.6 – 1 sec in children 1 – 1.5 sec in adolescent			
PS (with SIMV)	6 – 12 cm H2O (smaller ET tube à larger PS, for example use 12 cm H2O PS for 3 mm ETT, use 6 for 6 mm ETT)			

Modify the settings according to disease process & subsequent blood gases

*IBW: Estimated using growth chart (based on patient height)

Special Consideration:	
ARDS (and similar lung parenchyma diseases)	Asthma (And Similar Obstructive Diseases)
 Improve oxygenation by lung recruitment and protective lung strategy (high PEEP with low Vt) Tidal volume 4 - 6 ml/kg (keep plateau pressure < 30) PEEP increment up to 10 - 15 (maybe higher with caution) with high FiO2 requirement (> 50%) Use high Mean Airway Pressure (MAP) using longer Ti Could use inverse I:E ratio 1:1 or 2:1 (+deep sedation) Permissive hypercapnia (keep pH ≥ 7.2) High respiratory rate without air trapping (with low Vt) 	 Slow rate (below physiologic) Long expiratory time (1:4 - 1:5 I:E ratio) Watch for air-trapping (sedate deeply/paralyze in refractory cases with air trapping caused by triggering patient) Accept higher CO2 (Permissive hypercapnia). High PIP is temporarily acceptable (35 - 40) as long as the plateau pressure is < 30CmH2O

Useful Respiratory Equations					
Minute Ventilation:	VE = Respiratory rate x Tidal volume				
Alveolar-arterial gradient:	A-a gradient = PAO2 – PaO2				
Partial Alveolar O2 pressure:	PAO2 = FiO2 (PB* - 47) - 1.2 (PaCO2) *PB = Barometric Pressure				
Oxygen Content	CaO2: CaO2 = SaO2 x 1.34 x Hb				
O2 extraction	= (CaO2 – CvO2/CaO2) x 100				
Oxygen Index:	OI = FiO2 x MAP x 100 / PaO2				
Common hypoxemia Index	PaO2/FiO2 (< 300 in ARDS)				

Pediatric High Frequency Oscillatory Ventilation

HFOV General Principles

- · A continuous positive pressure system with piston displacement of gas & active exhalation
- Tidal volume delivered is less than anatomic dead space (1-3 ml/kg)
- Rates of 180 900 breaths per minute (3-15 Hertz)
- Lower inspiratory pressures as compared to Conventional ventilation (prevents barotrauma and volutrauma)

Main Indication:	Common Uses:
 Inadequate oxygenation that cannot be safely treated without potentially toxic ventilator settings with high risk of Ventilator Associated Lung Injury that can be defined by: Peak inspiratory pressure (PIP) > 30-35 cm H2O FiO2 > 0.60 with inability to wean it Mean airway pressure (Paw) > 15-20 cm H2O Peak End Expiratory Pressure (PEEP) > 10-15 cm H2O Oxygenation index > 13-15 	ARDS/ALI (most common use) Air leaks (pneumothorax, PIE) Persistent pulmonary hypertension (PPHN) Pulmonary hemorrhage Congenital diaphragmatic hernia Acute chest syndrome (SCD) Inadequate alveolar ventilation with respiratory acidosis

HFOV suggested Settings					
MAP/Paw (cmH2O)	 level of pressure held in the lung Supports oxygenation Used to optimize lung volume and, thus, alveolar surface area for gas exchange. Recruit atelectatic alveoli Prevent alveoli from collapsing (de-recruitment) Typically obtain a chest radiograph 1 hour after initiating HFOV then Q12-24 hours. 	 Initial MAP 2-5 cm higher than on CMV in neonates & 5-8 cmm higher in children Monitor degree of lung expansion by CXR diaphragm is at ~T9 on chest radiograph guard against overdistension. Alveolar atelectasis or overdistension can result in high pulmonary vascular resistance For V/Q matching, ensure adequate intravascular volume & cardiac output. 			
Power/ Amplitude/∆P (cmH2O)	 Volume of gas generated by each wave Inversely proportional to PaCO2 Start amplitude in the 30's and adjust until the "wiggle" extends to the groin. 	 Adjust in increments of 3 to 5 cm H2O Subjectively follow the wiggle Objectively follow PaCO2 			

	 number of breaths per second 10 Hz equal to 600 breath/ minutes lower Hz = increased tidal volume Start as per table and adjust by 1 at a time if needed 		Suggested starting frequency		
Frequency (Hertz)			Preterm Neonates	10 to 15 Hz	
			Term Neonates	8 to 10 Hz	
			Children	6 to 8 Hz	
Inspiratory Time (%):	Set at 33%, 1:2 ratio		Adult	5 to 6 Hz	

Trouble shooting with HFOV	Pitfalls with HFOV			
Hypoxemia	Suctioning should be done to ensure the ETT remains patent			
 Adjust FiO2 Increase MAP (diaphragm T9 on CXR) 	Frequency: every 12 to 24 hours and PRN. When? Decreased/absent wiggle Decrease in SpO2			
 Avoid overdistension (check CXRay) Avoid hypovolemia/hypotension 	Increase in CO2 level Avoid/minimize disconnect to suction (de-recruitment occurs quickly). De-recruitment may be minimized with closed suction system. Consider a sustained inflation recruitment maneuver post			
Hypercarpia	suctioning. Sedation:			
 Suction Pt using inline suction Increase POWER to increase ventilation 	Deeper sedation may be required. Neuromuscular blockade can be used in difficult/sensitive cases.			
 Decrease Frequency to increase tidal volume 	Complications of HFOV			
 Deflate cuff in ETT Monitor for a loss in Paw with the airleak created by deflating the cuff Increase Bias Flow to 30-40 L/ min 	Hypotension secondary to decreased venous return Pneumothorax ETT Obstruction from suboptimal mucus clearance			

Remember, the goal is not to achieve 'normal' PaCO2 and pH, but to minimize VALI.


Blood Products Transfusion

Blood Product	Receiver	Donor
	А	A, O
	В	B, O
Dealer d DDO an d Mile de Dia e d	0	0
Packed RBC and Whole Blood	AB	AB, A, B, O
	Rh-	Rh-
	Rh+	Rh+ or Rh-
	A	A, AB
Plasma or Platelet	В	B, AB
	AB	AB
	Rh+	Rh+ or Rh-
Platelet	Rh-	Rh- or Rh +*


*Give as an anti – D vaccine if the receiver is Rh-and the platelet concentration is Rh+


Blood Component	Dose	
pRBCs	10 – 20ml/kg over 3 – 4 hours	
Platelet	10ml/kg over 30 min	
FFP	10 – 20ml/kg over 1 hour	
Cryoprecipitate	5ml/kg over 30 min	

Pediatric Cardiac Arrest Algorithm



Rotate compressor every 2 minutes	Reversible Causes
 With bag & mask give 15:2 Compression to Ventilation Ratio 	Hypovolemia
 With advanced airway give 8-10 breath per minutes (continuous 	Нурохіа
chest compression)	Hydrogen ion (acidosis)
 Give epinephrine every 3-5 min 	Hypoglycemia
Dose: 0.01 mg/kg/dose (0.1 ml/kg/dose for 1:10,000 dilution)	Hypo/Hyperkalemia
0.1 mg/kg/dose via ETT if no IV/IO access (0.1 ml/kg for 1:1000 dilution)	Hypothermia
Shock energy dose after 2ed shock 4 J/kg or more (max 10 J/kg till)	Tension pneumothorax
adult dose 200 J)	Tamponade, cardiac
► Amiodarone dose: 5 mg/kg IV/IO bolus.	Toxins
(may repeat only once for refractory cases)	Thrombosis, pulmonary
► Lidocaine dose: 1 mg/kg IV/IO bolus	Thrombosis, coronary





References:

- · Pediatric and Neonatal Lexi- Drug, Lexicomp, Version 4.0.4 Copyright 2018
- BNF for Children (BNFC) 2016-2017, Sep 2016
- · The Teddy Bear Book, Pediatric Injectable Drugs, tenth edition, 2013
- Pediatric Critical Care, 5th Edition by Bradley P. Fuhrman MD FCCM (Author), Jerry J. Zimmerman MD PhD FCCM (Author)
- · Rogers' Textbook of Pediatric Intensive Care, Fourth Edition by David G. Nichols MD (Editor)
- Pilbeam's Mechanical Ventilation: Physiological and Clinical Applications, 6th Edition by J M Cairo PhD RRT (Author)
- Pediatric Critical Care Medicine: Basic Science and Clinical Evidence, 2007th Edition by Derek S. Wheeler (Editor), Hector R. Wong (Editor), Thomas P. Shanley (Editor)
- Pediatric Critical Care Study Guide: Text and Review, Apr 11, 2012 by Steven E. Lucking and Frank
 A. Maffei
- · The Harriet Lane Handbook, Twentieth Edition, 2015
- · Nelson Textbook of Pediatrics, 20e 20th Edition, 2016
- Pediatric Fundamental Critical Care Support, 2013 by Maureen A. Madden MSN CPNP-AC CCRN FCCM
- · American Dietetic Associate (ADA) Nutrition Care Manual, 2013 Edition
- · Handbook of Clinical Practice, January 2013, Sick Kids, Dr. Peter Cox (Editor)
- · Dosing Guidelines for Drugs Used in the Pediatric Critical Care Unit, 2009 Edition
- Pediatric Critical Care Medicine Handbook of Clinical Practice, Children Hospital, London Health Sciences Center
- Principles and Practice of Pediatric Infectious Diseases by Sarah S. Long, Larry K. Pickering & Charles G. Prober
- Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection, (IDSA Guidelines)
- · Surviving Sepsis Campaign, 2012
- Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glaser N, Jain V, Lee WWR, Mungai LNW, Rosenbloom AL, Sperling MA, Hanas R. A. Published in Pediatric Diabetes 2014: 15(Suppl. 20): 154-179. Uploaded: 2. Sept 2014
- BSPED Recommended Guideline for the Management of Children and Young People Under the Age of 18 Years with Diabetic Ketoacidosis, 2015
- Diabetic Ketoacidosis Protocol, British Columbia's Children's Hospital (October, 2015). British Columbia Children's Hospital
- · Up-to-date DKA Management, 2017
- · PALS/AHA Guideline, 2015
- Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016, A Rhodes, LE Evans, W Alhazzani, et al. Intensive Care Med, 43 (2017), pp. 304-377
- · Centers for Diabetes Control (CDC) and Prevention, 2016
- Carney N, Lujan S, Dikmen S, Temkin N, Petroni G, Pridgeon J, et al. Intracranial pressure monitoring in severe traumatic brain injury in latin america: process and methods for a multi-center randomized controlled trial. J Neurotrauma. 2012;29(11):2022-9.
- · Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, et al. Guidelines for the Man-

agement of Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15.

- Carney NA, Chesnut R, Kochanek PM, American Association for Surgery of T, Child Neurology S, International Society for Pediatric N, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Pediatr Crit Care Med. 2003;4(3 Suppl):S1.
- Hutchison JS, Ward RE, Lacroix J, Hebert PC, Barnes MA, Bohn DJ, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med. 2008;358(23):2447-56.
- Kochanek PM, Carney N, Adelson PD, Ashwal S, Bell MJ, Bratton S, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents--second edition. Pediatr Crit Care Med. 2012;13 Suppl 1:S1-82.
- Vavilala MS, Kernic MA, Wang J, Kannan N, Mink RB, Wainwright MS, et al. Acute care clinical indicators associated with discharge outcomes in children with severe traumatic brain injury. Crit Care Med. 2014;42(10):2258-66.
- Abend NS, Bearden D, Helbig I, McGuire J, Narula S, Panzer JA, et al. Status epilepticus and refractory status epilepticus management. Semin Pediatr Neurol. 2014;21(4):263-74.
- Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61.
- Smith DM, McGinnis EL, Walleigh DJ, Abend NS. Management of Status Epilepticus in Children. J Clin Med. 2016;5(4).
- Riviello JJ, Jr., Ashwal S, Hirtz D, Glauser T, Ballaban-Gil K, Kelley K, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2006;67(9):1542-50.
- Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3-23.
- Zeiler FA. Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus. Critical Care Research and Practice. 2015;2015:5.
- Fang Y, Wang X. Ketamine for the treatment of refractory status epilepticus. Seizure. 2015;30:14-20.
- Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498-503.
- Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105(1-2):183-8.
- Abend NS, Arndt DH, Carpenter JL, Chapman KE, Cornett KM, Gallentine WB, et al. Electrographic seizures in pediatric ICU patients: cohort study of risk factors and mortality. Neurology. 2013;81(4):383-91.
- Abend NS, Chapman KE, Gallentine WB, Goldstein J, Hyslop AE, Loddenkemper T, et al. Electroencephalographic monitoring in the pediatric intensive care unit. Curr Neurol Neurosci Rep. 2013;13(3):330.
- Igartua J, Silver P, Maytal J, Sagy M. Midazolam coma for refractory status epilepticus in children. Crit Care Med. 1999;27(9):1982-5.
- Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol. 2008;38(6):377-90.

🌐 www.moh.gov.sa | 🗞 937 | 比 SaudiMOH | 🛎 MOHPortal | 🗟 SaudiMOH | 🗅 Saudi_Moh